expert report of barbara d. beck, ph.d., dabt, ats, ert in the...

Expert Report of

Barbara D. Beck, Ph.D., DABT, ATS, ERT

in the Matter of

State of Minnesota vs. 3M Company

Prepared by

Barbara D. Beck, Ph.D., DABT, ATS, ERT

Prepared for

Brewer Attorneys & Counselors

1717 Main Street, Suite 4800

Dallas, Texas 75201

November 3, 2017

27-CV-10-28862Electronically Served11/3/2017 11:40 PMHennepin County, MN

i

\\camfs\G_Drive\Projects\214032.60_Minnesota\TextProc\r110317a.docx

Table of Contents

Page

1 Introduction ........................................................................................................................ 1

1.1 Case Overview ......................................................................................................... 1

1.2 Qualifications of Dr. Barbara D. Beck...................................................................... 1

2 Summary of Opinions ......................................................................................................... 3

2.1 Summary of Primary Opinions ................................................................................ 3

2.2 Methodology ........................................................................................................... 4

2.3 PFC Chemistry and Monitoring ............................................................................... 4

2.4 ADME/PBPK and Modes of Action .......................................................................... 4

2.5 Animal and Human Studies ..................................................................................... 6

2.6 Evaluation of US EPA and Minnesota Toxicity Criteria and Environmental

Guideline Levels ...................................................................................................... 6

2.7 Evaluation of Data in Specific Locations at Issue .................................................... 9

2.8 State of Knowledge ............................................................................................... 13

2.9 Comments on Plaintiff's Expert Reports ............................................................... 14

3 Methodology ..................................................................................................................... 15

3.1 Information Used and Analyses Performed ......................................................... 15

3.2 Evaluating Risks from Chemical Exposures ........................................................... 16

3.2.1 Introduction to Toxicology ........................................................................ 16

3.2.2 Introduction to Epidemiology ................................................................... 18

3.2.3 Extrapolation from Animals to Humans ................................................... 18

3.2.4 Toxicity Criteria ......................................................................................... 19

3.2.5 Risk Assessment Methodology ................................................................. 20

3.2.6 Regulatory Toxicology vs. Causation Analysis .......................................... 22

3.2.7 Evaluating the Weight of Evidence ........................................................... 22

4 Overview of PFC Chemistry, Properties, Production, Disposal, and Monitoring ............. 24

4.1 The Chemistry of PFCs .......................................................................................... 24

4.2 Environmental and Biological Properties of PFCs ................................................. 25

4.3 The Synthesis of PFCs ............................................................................................ 25

4.4 3M Production of PFOA and PFOS ........................................................................ 26

4.5 PFC Waste Disposal ............................................................................................... 26

4.6 PFC Monitoring Programs ..................................................................................... 27

5 Understanding Mechanisms of Toxicity ........................................................................... 29

5.1 Absorption, Distribution, Metabolism, and Excretion .......................................... 29

5.1.1 Absorption ................................................................................................ 29

5.1.1.1 Rats and Mice ............................................................................. 30

27-CV-10-28862

ii


5.1.1.2 Monkeys and Humans ................................................................ 30

5.1.2 Distribution ............................................................................................... 31

5.1.2.1 Volume of Distribution ............................................................... 31

5.1.2.2 Tissue Distribution ...................................................................... 32

5.1.2.3 Placental and Lactational Transfer ............................................. 36

5.1.3 Metabolism ............................................................................................... 37

5.1.4 Excretion ................................................................................................... 37

5.1.4.1 Sex Differences in Excretion ....................................................... 40

5.1.4.2 Excretion via Menstruation and Lactation ................................. 41

5.1.4.3 Accounting for Interspecies Differences in Elimination Half-

lives ............................................................................................. 41

5.2 Physiologically Based Pharmacokinetic (PBPK) Models ....................................... 42

5.3 PPARα Mode of Action Associated with a Species-specific Response for

PFOA ...................................................................................................................... 44

5.3.1 PPARα and PFOA Liver Effects .................................................................. 45

5.3.2 PPARα and PFOA Immunological Effects .................................................. 46

5.3.3 PPARα and PFOA Developmental Effects ................................................. 47

5.3.4 Implications of a PPARα Mode of Action for Minnesota's PFOA

Drinking Water Guideline ......................................................................... 48

6 Animal Studies .................................................................................................................. 49

6.1 PFOA ...................................................................................................................... 50

6.1.1 Key Endpoints ........................................................................................... 50

6.1.1.1 Liver Effects ................................................................................ 50

6.1.1.2 Serum Lipid Effects ..................................................................... 53

6.1.1.3 Thyroid Hormone-related Effects ............................................... 54

6.1.1.4 Immunotoxicity Effects ............................................................... 55

6.1.1.5 Developmental and Reproductive Effects .................................. 59

6.1.2 Cancer ....................................................................................................... 60

6.1.3 Overall Conclusions for PFOA ................................................................... 61

6.2 PFOS ...................................................................................................................... 62

6.2.1 Key Endpoints ........................................................................................... 62

6.2.1.1 Liver Effects ................................................................................ 63

6.2.1.2 Serum Lipid Effects ..................................................................... 65

6.2.1.3 Thyroid Hormone-related Effects ............................................... 67

6.2.1.4 Immunotoxicity Effects ............................................................... 69

6.2.1.5 Developmental and Reproductive Effects .................................. 72

6.2.2 Morbidity and Mortality ........................................................................... 74

6.2.3 Cancer ....................................................................................................... 74

6.2.4 Overall Conclusions for PFOS .................................................................... 75

6.3 PFBA ...................................................................................................................... 76

6.3.1 Liver Effects ............................................................................................... 76

6.3.2 Serum Lipid Effects ................................................................................... 76

6.3.3 Thyroid Hormone-related Effects ............................................................. 76

27-CV-10-28862

iii


6.3.4 Developmental and Reproductive Effects ................................................ 77

6.4 PFBS ....................................................................................................................... 77

6.4.1 Liver Effects ............................................................................................... 77

6.4.2 Serum Lipid Effects ................................................................................... 77

6.4.3 Kidney Effects ............................................................................................ 78

6.4.4 Blood Effects ............................................................................................. 78

6.4.5 Thyroid Hormone-related Effects ............................................................. 78

6.4.6 Developmental and Reproductive Effects ................................................ 78

6.5 Overall Conclusions for Animal Toxicity ............................................................... 79

7 Human Studies .................................................................................................................. 80

7.1 PFOA ...................................................................................................................... 80

7.1.1 Serum Concentrations in Workers ............................................................ 80

7.1.2 Occupational Health Studies ..................................................................... 82

7.1.2.1 Reproductive and Developmental Effects .................................. 82

7.1.2.2 Liver Enzymes and Disease ......................................................... 82

7.1.2.3 Serum Lipids and Cardiovascular Disease .................................. 83

7.1.2.4 Immunological Effects ................................................................ 87

7.1.2.5 Kidney Effects ............................................................................. 87

7.1.2.6 Cancer ......................................................................................... 88

7.1.3 Serum Concentrations in the General Population and Non-

occupationally Exposed Cohorts ............................................................... 90

7.1.4 Studies in the General Population ............................................................ 95

7.1.4.1 Reproductive and Developmental Effects .................................. 95

7.1.4.2 Liver Enzymes and Disease ......................................................... 99

7.1.4.3 Thyroid Hormones and Disease ................................................ 100

7.1.4.4 Serum Lipids and Cardiovascular Disease ................................ 101

7.1.4.5 Immunological Effects .............................................................. 103

7.1.4.6 Kidney Effects ........................................................................... 106

7.1.4.7 Cancer ....................................................................................... 106

7.1.5 C8 Science Panel ..................................................................................... 108

7.1.5.1 High Cholesterol ....................................................................... 109

7.1.5.2 Thyroid Disease ........................................................................ 109

7.1.5.3 Pregnancy-induced Hypertension and Preeclampsia............... 110

7.1.5.4 Ulcerative Colitis ....................................................................... 111

7.1.5.5 Kidney Cancer ........................................................................... 111

7.1.5.6 Testicular Cancer ...................................................................... 112

7.1.5.7 Overall Conclusions for C8 Science Panel ................................. 113

7.1.6 Overall Conclusions for Human Studies of PFOA .................................... 113

7.2 PFOS .................................................................................................................... 114

7.2.1 Serum Concentrations in Workers .......................................................... 114

7.2.2 Health Endpoint Studies in Workers ....................................................... 115

7.2.2.1 Reproductive and Developmental Effects ................................ 116

7.2.2.2 Liver Enzymes ........................................................................... 116

27-CV-10-28862

iv


7.2.2.3 Liver Disease ............................................................................. 117

7.2.2.4 Serum Lipids ............................................................................. 117

7.2.2.5 Cardiovascular Disease ............................................................. 118

7.2.2.6 Cancer ....................................................................................... 119

7.2.3 Serum Concentrations in the General Population and Non-

occupational Exposed Cohorts ............................................................... 120

7.2.4 Studies in the General Population .......................................................... 122


7.2.4.2 Liver Enzymes and Disease ....................................................... 133


7.2.4.4 Serum Lipids and Cardiovascular Disease ................................ 136


7.2.4.6 Kidney Effects ........................................................................... 141

7.2.4.7 Cancer ....................................................................................... 142

7.2.5 Overall Conclusions for Human Studies .................................................. 143

7.3 PFBA and PFBS .................................................................................................... 143

7.3.1 PFBA and PFBS Exposure ........................................................................ 143

7.3.2 Studies in the General Population and Non-occupationally Exposed

Populations ............................................................................................. 143



7.3.2.3 Serum Lipids ............................................................................. 144


7.4 Overall Conclusions ............................................................................................. 145

8 Agency Guidelines ........................................................................................................... 146

8.1 PFOA .................................................................................................................... 147

8.1.1 US EPA ..................................................................................................... 147

8.1.1.1 RfD ............................................................................................ 147

8.1.1.2 Drinking Water ......................................................................... 148

8.1.2 Minnesota ............................................................................................... 149

8.1.2.1 RfD (2008) ................................................................................. 149

8.1.2.2 HRL ............................................................................................ 149

8.1.2.3 RfD (2017) ................................................................................. 149

8.1.2.4 HBV ........................................................................................... 150

8.1.2.5 Soil ............................................................................................ 151

8.2 PFOS .................................................................................................................... 152

8.2.1 US EPA ..................................................................................................... 152

8.2.1.1 RfD ............................................................................................ 152

8.2.1.2 Drinking Water ......................................................................... 152

8.2.2 Minnesota ............................................................................................... 153

8.2.2.1 RfD (2008) ................................................................................. 153

8.2.2.2 HRL ............................................................................................ 154

8.2.2.3 RfD (2017) ................................................................................. 154

27-CV-10-28862

v


8.2.2.4 HBV ........................................................................................... 155

8.2.2.5 Soil ............................................................................................ 156

8.3 PFBA .................................................................................................................... 156

8.3.1 RfD ........................................................................................................... 156

8.3.2 Water ...................................................................................................... 156

8.3.3 Soil ........................................................................................................... 157

8.4 PFBS ..................................................................................................................... 157

8.4.1 US EPA ..................................................................................................... 157

8.4.1.1 RfD ............................................................................................ 157

8.4.1.2 Water ........................................................................................ 158

8.4.1.3 Soil ............................................................................................ 158

8.4.2 Minnesota ............................................................................................... 158

8.4.2.1 RfD ............................................................................................ 158

8.4.2.2 Water ........................................................................................ 159

8.5 PFHxS ................................................................................................................... 159

8.6 Relative Source Contribution .............................................................................. 159

8.7 Comparison of Drinking Water Guidelines to Animal Data ................................ 160

8.8 Minnesota's Calculation of Health Risk Indices .................................................. 162

8.9 Characteristics of Hazardous Waste Under Minnesota Rules Part 7045.0131 .. 163

9 Site Data .......................................................................................................................... 165

9.1 Data Processing and Compilation ....................................................................... 165

9.2 Groundwater ....................................................................................................... 168

9.3 Surface Water ..................................................................................................... 169

9.4 Soil ....................................................................................................................... 170

9.5 Sediment ............................................................................................................. 170

9.6 Fish ...................................................................................................................... 171

10 Evaluation of Site Data .................................................................................................... 173

10.1 Potentially Exposed Populations ........................................................................ 173

10.2 Development of Exposure Point Concentrations ............................................... 174

10.3 Exposure Equations and Assumptions ................................................................ 175

10.3.1 Ingestion of PFCs in Groundwater .......................................................... 175

10.3.2 Ingestion of PFCs in Sediment ................................................................ 176

10.3.3 Dermal Contact with PFCs in Sediment .................................................. 177

10.3.4 Ingestion of PFCs in Surface Water ......................................................... 177

10.3.5 Ingestion of PFCs in Fish ......................................................................... 178

10.4 Comparison of Exposures with the PODs Used to Set Agency Guidelines ......... 178

10.4.1 Past Adult Female Resident's Exposures to PFCs in Private Wells ......... 179

10.4.2 Past Adult Female Resident's Exposures to PFCs in City Wells............... 180

10.4.3 Current Adult Female Resident's Exposures to PFCs in Private Wells .... 180

10.4.4 Current Adult Female Resident's Exposures to PFCs in City Wells ......... 181

10.4.5 Adult Female Recreational User's Exposure to PFCs .............................. 181

27-CV-10-28862

vi


10.5 Comparison of Resident PFC Serum Concentrations with Worker and

Animal PFC Serum Concentrations ..................................................................... 182

10.6 Conclusions ......................................................................................................... 185

11 Development of Scientific Knowledge of PFC Toxicity Over Time.................................. 196

11.1 Introduction ........................................................................................................ 196

11.1.1 Analytical Methodology.......................................................................... 196

11.1.2 Bioaccumulation ..................................................................................... 198

11.2 Overview of the Chronology of 3M Scientific Knowledge and Actions .............. 198

11.2.1 1970s....................................................................................................... 198

11.2.2 1980s....................................................................................................... 199

11.2.3 1990s....................................................................................................... 200

11.4.4 Early 2000s .............................................................................................. 201

11.3 Summary ............................................................................................................. 202

12 Awareness of Health Risks from Waste Disposal ........................................................... 204

12.1 Waste Disposal and Contamination of Groundwater......................................... 204

12.2 Awareness of Chemicals in the Environment ..................................................... 206

12.3 Summary ............................................................................................................. 207

13 Comments on Plaintiff's Opinions .................................................................................. 208

13.1 Comments on Dr. DeWitt's Opinions.................................................................. 208

13.1.1 Cancer ..................................................................................................... 209

13.1.2 Developmental Toxicity .......................................................................... 212

13.1.3 Immunotoxicity ....................................................................................... 213

13.1.4 Thyroid Disease....................................................................................... 214

13.1.5 Consideration of Dose............................................................................. 215

13.1.6 Consideration of Causation..................................................................... 216

13.1.7 Consideration of Risk Assessment .......................................................... 216

13.1.8 Drinking Water Guidance........................................................................ 216

13.1.9 State of Knowledge................................................................................. 217

13.1.10 Appendix B: Estimating "Safe" PFOS Doses.......................................... 219

13.2 Comments on Dr. Grandjean's Opinions ............................................................ 219

13.2.1 Immunotoxicity ....................................................................................... 220

13.2.2 Reproductive and Developmental Outcomes ........................................ 223

13.2.3 Cancer ..................................................................................................... 225

13.2.4 Other Endpoints...................................................................................... 229

13.2.5 State of Knowledge................................................................................. 229

13.2.6 Serum Analyses from Minnesota Residents ........................................... 234

13.2.7 Alternative Drinking Water Limits .......................................................... 234

13.3 Comments on Dr. Sunding's Opinions ................................................................ 235

References .................................................................................................................................. 237

27-CV-10-28862

vii


Appendix A Curriculum Vitae and Testimony Table (Last 4 Years) of Barbara D. Beck,

Ph.D., DABT, ATS, ERT

Appendix B Absorption, Distribution, Metabolism, and Excretion Data

Appendix C Site Data

Appendix D Exposure Calculations

Appendix E Other Materials Considered

27-CV-10-28862

viii


List of Tables

Table 2.1 Comparative Doses from Animal Studies: Number of 8 oz. Glasses of Water at the HBV

an Adult Would Need to Drink to Reach the Serum Concentrations Used as the Basis for

the HBVs

Table 2.2 Lowest MOE Values for Specific Pathways

Table 2.3 MOEs Based on 95th Percentile Serum Concentrations in Southern Washington County

Residents

Table 4.1 PFCs with a Sulfonate Functional Group

Table 4.2 PFCs with a Carboxylate Functional Group

Table 5.1 PFC Volume of Distribution Values in Humans, Monkeys, Rates, and Mice (L/kg)

Table 5.2 Tissue Distribution of PFCs by Species and Sex

Table 5.3 PFC Liver to Serum Ratios

Table 5.4 Liver Tissue Distribution Across Species, Sex, and Dose

Table 5.5 Placental and Lactational Transfer

Table 5.6 PFC Elimination Half-lives

Table 5.7 Comparison of Developmental Effects in Wild-type vs. PPARα-knockout Mice

Table 7.1 Serum PFOA (ng/mL) in Representative Occupational Populations

Table 7.2 Serum PFOA (ng/mL) in Representative Non-occupational Populations

Table 7.3 Non-occupational PFOA Cohorts

Table 7.4 Summary of 3M Occupational PFOS Serum Concentrations (ppb or ng/mL)

Table 7.5 Serum PFOS (ng/mL) in Representative Non-occupational Populations

Table 7.6 Non-occupational PFOS Cohorts

Table 8.1 Comparative Doses from Animal Studies: Number of 8 oz. Glasses of Water at the

Guideline Concentrations an Adult Would Need to Drink to Reach the NOEL or LOEL

Used as the Basis for PFC Guidance Values

Table 9.1 Summary of Files Containing Sample Results

Table 9.2 Groundwater Location Types

27-CV-10-28862

ix


Table 9.3 Data Availability and Generalized Data Grouping Areas for Named Water Bodies

Table 9.4 Fish Sample Types, by Water Body Type

Table 9.5 Summary of Reported Fish Data Units Basis

Table 10.1 Summary of Hypothetical Daily Intakes and Margins of Exposure for Past Resident's

Groundwater Exposure for Private Wells

Table 10.2 Summary of Hypothetical Daily Intakes and Margins of Exposure for Past Resident's

Groundwater Exposure from City Wells

Table 10.3 Summary of Hypothetical Daily Intakes and Margins of Exposure for Current (2014-2017)

Resident's Groundwater Exposure from Private Wells with Highest Exposure Estimates

Table 10.4 Summary of Hypothetical Daily Intakes and Margins of Exposure for Current (2014-2017)

Resident's Groundwater Exposure from City Wells

Table 10.5 Summary of Hypothetical Daily Intakes and Margins of Exposure for Past and Current

Recreational User

Table 10.6 Serum Concentrations of PFOA and PFOS in Southern Washington County Residents

Compared to the US Population


Compared to 3M Workers, MDH LOEL/NOEL, and Chang et al. (2017) Study

Table 10.8 Margin of Exposure Comparisons Based on Serum Concentrations in Southern

Washington County Residents

27-CV-10-28862

x


List of Figures Within the Report

Figure 4.1 Chemical Structures of PFOA, PFOS, PFBA, and PFBS

Figure 9.1 Interrogatory Boundary

Figure 9.2 Site and Landfill Boundaries

27-CV-10-28862

xi


Abbreviations

3M 3M Company

ACGIH American Conference of Governmental Industrial Hygienists

Acox1 Acyl Coenzyme A Oxidase

ADHD Attention Deficit/Hyperactivity Disorder

ADME Absorption, Distribution, Metabolism, and Excretion

ALP Alkaline Phosphatase

ALSPAC Avon Longitudinal Study of Parents and Children

ALT Alanine Aminotransferase

AOR Adjusted Odds Ratio

APFO Ammonium Perfluorooctanoate

ASD Autism Spectrum Disorder

AST Aspartate Aminotransferase

ATSDR Agency for Toxic Substances and Disease Registry

AUC Area Under the Curve

BMCL5 Benchmark Concentration for a 5% Response

BMDL10 Benchmark Dose Level for a 10% Response

BMI Body Mass Index

C8 Cohort C8 Health Project Cohort

CCK Cholescystokinin

CDC Centers for Disease Control and Prevention

CERCLA Comprehensive Environmental Response, Compensation, and Liability Act

CHEF Children's Health and Environment in the Faroe Islands

CHirP Chemicals, Health, and Pregnancy

CI Confidence Interval

CIMT Carotid Intima Media Thickness

CNS Central Nervous System

ConA Concanavalin A

COPC Constituent of Potential Concern

CSF Cancer Slope Factor

CVD Cardiovascular Disease

DA Dermal Absorption Fraction

Danish EPA Danish Environmental Protection Agency

DCH Diet, Cancer, and Health

DWEL Drinking-water-equivalent Level

DWI Drinking Water Intake

ECF Electrochemical Fluorination

ED-RIA Equilibrium Dialysis Followed by Radioimmunoassay

EFSA European Food Safety Authority

eGFR Estimated Glomerular Filtration Rate

Ehhadh Enoyl Coenzyme A Hydratase

ELCR Excess Lifetime Cancer Risk

EPC Exposure Point Concentration

F0 Parental Generation

27-CV-10-28862

xii


F1 First Generation

F2 Second Generation

FA Fraction Absorbed

FAI Free Androgen Index

FSH Follicle-stimulating Hormone

GAC Granular Activated Carbon

GACA Genetics and Biomarkers Study for Childhood Asthma

GD Gestational Day

GFR Glomerular Filtration Rate

GGT Gamma-glutamyl Transferase

GWSS Ground Water Supply Survey

HA Health Advisory

HBV Health-based Value

HDL High-density Lipoprotein

HED Human Equivalent Dose

HI Hazard Index

hPPARα Humanized Peroxisome Proliferator-activated Receptor α

HQ Hazard Quotient

HR Hazard Ratio

HRI Health Risk Index

HRL Health Risk Limit

IARC International Agency for Research on Cancer

IFN-γ Interferon Gamma

Ig Immunoglobulin

IgA Immunoglobulin A

IgE Immunoglobulin E

IgG Immunoglobulin G

IgM Immunoglobulin M

IHD Ischemic Heart Disease

IL-2 Interleuken 2

IL-4 Interleuken 4

IL-5 Interleuken 5

INUENDO Biopersistent Organochlorines in Diet and Human Fertility

IQR Interquartile Range

IRIS Integrated Risk Information System

IRR Incidence Rate Ratio

IUR Inhalation Unit Risk

iv Intravenous

Kow Octanol-Water Partition Coefficient

LD50 Median Lethal Dose

LDL Low-density Lipoprotein

LH Luteinizing Hormone

LOAEL Lowest Observed Adverse Effect Level

LOEL Lowest Observed Effect Level

LOQ Limit of Quantitation

MCL Maximum Contaminant Level

MDH Minnesota Department of Health

Minnesota State of Minnesota

27-CV-10-28862

xiii


MIRC Maternal-Infant Research on Environmental Chemicals

MMR Measles, Mumps, and Rubella

MoA Mode of Action

MOE Margin of Exposure

MPCA Minnesota Pollution Control Agency

N-EtFOSE N-ethyl Perfluorooctanesulfonamido Ethanol

NAS National Academy of Sciences

NHANES National Health and Nutrition Examination Survey

NK Natural Killer

NOAEL No Observed Adverse Effect Level

NOEL No Observed Effect Level

NPL National Priorities List

NRC National Research Council

NTP National Toxicology Program

OAT Organic Anion Transporter

Oatp Organic Anion Transporting Polypeptide

OECD Organisation for Economic Co-operation and Development

OR Odds Ratio

PBPK Physiologically Based Pharmacokinetic

PFBA Perfluorobutanoic Acid

PFBS Perfluorobutane Sulfonate

PFC Perfluorinated Chemical

PFHxA Perfluorohexanoic Acid

PFHxS Perfluorohexane Sulfonate

PFOA Perfluorooctanoic Acid

PFOS Perfluorooctane Sulfonate

PFPeA Perfluoropentanoic Acid

PND Post-natal Day

POD Point of Departure

PPARα Peroxisome Proliferator-activated Receptor α

ppb Parts Per Billion

ppm Parts Per Million

PXR Pregnane X Receptor

QC Quality Control

RAGS Risk Assessment Guidance for Superfund

RCRA Resource Conservation and Recovery Act

RfC Reference Concentration

RfD Reference Dose

RME Reasonable Maximum Exposure

RSC Relative Source Contribution

RSL Regional Screening Level

SARA Superfund Amendments and Reauthorization Act

SDWA Safe Drinking Water Act

SGA Small for Gestational Age

SHBG Sex-hormone-binding Globulin

SIR Standardized Incidence Ratio

siRNA Small Interference RNA

SMR Standard Mortality Ratio

27-CV-10-28862

xiv


SRBC Sheep Red Blood Cell

SRV Soil Reference Value

T3 Triiodothyronine

T4 Thyroxine

TDAR T-cell-dependent Antibody Response

TGAb Thyroglobulin Antibody

TIAR T-cell-independent Antibody Response

TMAb Thyroid Microsomal Antibody

TNP Trinitrophenyl

TPOAb Thyroid Peroxidase Antibody

TRH Thyrotropin-releasing Hormone

TSCA Toxic Substances Control Act

TSH Thyroid-stimulating Hormone

TTP Time to Pregnancy

TWA Time-weighted Average

UCLM Upper Confidence Limit on the Mean

UF Uncertainty Factor

UK FSA United Kingdom Food Standards Authority

UK United Kingdom

UN Minnesota Unique Well Number

US United States

US EPA United States Environmental Protection Agency

USGS United States Geological Survey

Vd Volume of Distribution

VLDL Very Low Density Lipoprotein

VOC Volatile Organic Compound

27-CV-10-28862

1


1 Introduction

1.1 Case Overview

curriculum vitae

1.2 Qualifications of Dr. Barbara D. Beck

cum laude

27-CV-10-28862

2


et al et al

et al vs

vs

vs. vs.

27-CV-10-28862

3


2 Summary of Opinions

2.1 Summary of Primary Opinions

vs

§

§

§

§

§

i.e

§

§

§

§

e.g

27-CV-10-28862

4


2.2 Methodology

2.3 PFC Chemistry and Monitoring

2.4 ADME/PBPK and Modes of Action

27-CV-10-28862

5


in

utero via

27-CV-10-28862

6


2.5 Animal and Human Studies

i.e

e.g

e.g.

Animal Studies.

Human Studies.

i.e

2.6 Evaluation of US EPA and Minnesota Toxicity Criteria and Environmental

Guideline Levels

27-CV-10-28862

7


§

§

i.e

§

§

§

§

27-CV-10-28862

8


§

§

§

§

§

§

§

§

§

i.e

§

§

27-CV-10-28862

9


Table 2.1 Comparative Doses from Animal Studies: Number of 8 oz. Glasses of Water at the HBV an Adult

Would Need to Drink to Reach the Serum Concentrations Used as the Basis for the HBVsa

PFC

Agency

Guidance

(mg/L)

Study/

Species Effects

LOEL/

NOEL

Dose

(mg/kg-day)

HED

(mg/kg-day)

Intake of Water at

Guideline Value

Needed for a 70 kg

Adult to Reach the HED

L/Day 8 oz. Glasses/

Day

PFOA MDH HBV =

0.000035

Lau et al.

(2006)/

Mouse

Delayed

skeletal

ossification,

accelerated

male

puberty

LOEL 1 0.0053 11,000 45,000

PFOS MDH HBV =

0.000027

Luebker et

al. (2005a)/

Rat

Reduced

weight gain

in F2 pups

NOEL 0.1 0.00051 1,300 5,600

Notes:

F2 = Second Generation; HBV = Health-based Value; HED = Human Equivalent Dose; LOEL = Lowest Observed Effect Level; MDH =

Minnesota Department of Health; NOEL = No Observed Effect Level; PFC = Perfluorinated Chemical; PFOA = Perfluorooctanoic Acid;

PFOS = Perfluorooctane Sulfonate.

(a) Water intake is rounded to two significant digits.

2.7 Evaluation of Data in Specific Locations at Issue

i.e

27-CV-10-28862

10


i.e

27-CV-10-28862

11


Table 2.2 Lowest MOE Valuesa for Specific Pathways

PFC POD

(mg/kg-day)

Past

Hypothetical

Exposure,

Private Well

with Highest

Concentration

Past

Hypothetical

Exposure,

City Well with

Highest

Concentration

Current

Hypothetical

Exposure,

Private Well

with Highest

Concentration

Current

Hypothetical

Exposure,

City Well with

Highest

Concentration

Hypothetical

Exposure,

Adult Female

Recreational

User

PFOA 0.0053 50 190 170 1,000 3,200

PFOSb 0.00051 4.3 12 31 83 4.6

PFOSc 0.002 17 47 120 330 18

PFBA 0.86 1,100 10,000 5,000 21,000 2,400,000

PFBS 0.42 39,000 39,000 170,000 220,000 1,500,000

Notes:

PFBA = Perfluorobutanoic Acid; PFBS = Perfluorobutane Sulfonate; PFC = Perfluorinated Chemical; PFOA = Perfluorooctanoic

Acid; PFOS = Perfluorooctane Sulfonate; POD = Point of Departure.

(a) MOEs rounded to two significant digits.

(b) POD selected by US EPA and MDH.

(c) Alternative and better-supported POD (see Section 2.6).

i.e

27-CV-10-28862

12


Table 2.3 MOEs Based on 95th Percentile Serum Concentrations in

Southern Washington County Residents

PFC Animal Serum POD

(μg/L) Year

95th Percentile Serum

Concentrations in Residents

(μg/L)

MOEa

PFOA 38,000

(LOEL)b,c

2008 60 630

2010 49 780

2014 26 1,500

PFOS 6,260

(NOEL)b

2008 100 63

2010 70 90

2014 70 89

PFOS 25,000

(NOEL)d

2008 100 250

2010 70 360

2014 70 360

Notes:

LOEL = Lowest Observed Effect Level; MOE = Margin of Exposure; NOEL = No Observed

Effect Level; PFC = Perfluorinated Chemical; PFOA = Perfluorooctanoic Acid; PFOS =

Perfluorooctane Sulfonate; POD = Point of Departure.

(a) MOE = POD / Serum Concentration. MOEs were rounded to two significant digits.

(b) Serum concentrations at the US EPA/MDH POD.

(c) Using the more scientifically supported POD would change the PFOA LOEL to a NOEL.

(d) Based on a more scientifically supported NOEL of 0.4 mg/kg-day (see Section 8.2).

27-CV-10-28862

13


2.8 State of Knowledge

27-CV-10-28862

14


e.g

2.9 Comments on Plaintiff's Expert Reports

27-CV-10-28862

15


3 Methodology

3.1 Information Used and Analyses Performed

§

§

§

§

§

§

§

§

§

27-CV-10-28862

16


§

§

3.2 Evaluating Risks from Chemical Exposures

3.2.1 Introduction to Toxicology

et al

et al

et al et al

27-CV-10-28862

17


et al et al et al et al

et al

et al

via

et al et al et al et al et al

Principles and Methods of Toxicology et al

e.g. et al.

et al et

al

§

§

§ i.e

§

§

§

§

§

27-CV-10-28862

18


et al

et al

3.2.2 Introduction to Epidemiology

et al

et al

e.g.

versus

et al

et al

3.2.3 Extrapolation from Animals to Humans

et al. et al

et al

27-CV-10-28862

19


et al

3.2.4 Toxicity Criteria

i.e

via

i.e.

etc.

i.e

i.e

et al

27-CV-10-28862

20


et al et al

3.2.5 Risk Assessment Methodology

Hazard Identification:

Dose-Response Assessment:

Exposure Assessment:

Risk Characterization:

!"#"$%&'()*+,-* = ./0)1($,&2)-3,-*$"*+)-&456789:;,<,$,-3,&2)-3,-*$"*+)-&456789:

27-CV-10-28862

21


et al.

i.e.

e.g.

i.e.

e.g.

i.e

27-CV-10-28862

22


3.2.6 Regulatory Toxicology vs. Causation Analysis

versus

unlikely

i.e.

actual

et al

i.e.

3.2.7 Evaluating the Weight of Evidence

27-CV-10-28862

23


et al

Strength of the Association:

Consistency:

Specificity:

Temporality:

Biological Gradient:

i.e.

Plausibility:

Coherence:

Experiment: i.e.

Analogy:

27-CV-10-28862

24


4 Overview of PFC Chemistry, Properties, Production,

Disposal, and Monitoring

4.1 The Chemistry of PFCs

PFOA

PFOS

PFBA

PFBS

Figure 4.1 Chemical Structures of PFOA, PFOS, PFBA, and PFBS.13 PFBA =

Perfluorobutanoic Acid; PFBS = Perfluorobutane Sulfonate; PFOA = Perfluorooctanoic

Acid; PFOS = Perfluorooctane Sulfonate.

et al

27-CV-10-28862

25


Table 4.1 PFCs with a Sulfonate Functional Group

Compound Abbreviation Carbon Length

Perfluorobutane Sulfonate PFBS 4

Perfluorohexane Sulfonate PFHxS 6

Perfluorooctane Sulfonate PFOS 8

Perfluorodecane Sulfonate PFDS 10

Table 4.2 PFCs with a Carboxylate Functional Group

Compound Abbreviation Carbon Length

Perfluorobutanoic Acid PFBA 4

Perfluoropentanoic Acid PFPeA 5

Perfluorohexanoic Acid PFHxA 6

Perfluoroheptanoic Acid PFHpA 7

Perfluorooctanoic Acid PFOA 8

Perfluorononanoic Acid PFNA 9

Perfluorodecanoic Acid PFDA 10

Perfluoroundecanoic Acid PFUnA 11

Perfluorododecanoic Acid PFDoA 12

Perfluorotetradecanoic Acid PFTA 14

4.2 Environmental and Biological Properties of PFCs

et al

et al

4.3 The Synthesis of PFCs

27-CV-10-28862

26


)

4.4 3M Production of PFOA and PFOS

et al.

e.g

4.5 PFC Waste Disposal

27-CV-10-28862

27


4.6 PFC Monitoring Programs

27-CV-10-28862

28


27-CV-10-28862

29


5 Understanding Mechanisms of Toxicity

5.1 Absorption, Distribution, Metabolism, and Excretion

5.1.1 Absorption

e.g

e.g

27-CV-10-28862

30


5.1.1.1 Rats and Mice

et al et

al vs

et al

vs

et al

et al

et al et al

et al

5.1.1.2 Monkeys and Humans

et al

via e.g

et al et al et al et al et al

et al in vitro

et al

via

27-CV-10-28862

31


5.1.2 Distribution

e.g

5.1.2.1 Volume of Distribution

e.g

et al et al et al

i.e i.e

27-CV-10-28862

32


Table 5.1 PFC Volume of Distribution Values in Humans, Monkeys, Rats, and Mice (L/kg)

Species Sex Exposure

Route PFBA PFBS PFOA PFOS

Humansa N/A N/A N/A 0.170 0.230

Cynomolgus Monkeysb Females iv 0.443 0.255 0.198 0.274

Males 0.526 0.254 0.181 0.202

Sprague-Dawley Ratsc Females iv 0.187 0.351 N/A 0.586

Males 0.253 0.330 N/A 0.649

Sprague-Dawley Ratsd Females iv N/A N/A 0.171 0.352

Males N/A N/A 0.112 0.383

Sprague-Dawley Ratsc Females Oral 0.173 0.391 N/A 0.521

Males 0.209 0.676 N/A 0.765

Sprague-Dawley Ratsd Females Oral N/A N/A 0.154 0.289

Males N/A N/A 0.106 0.280

Wistar Ratse Females iv N/A N/A 0.211 N/A

Males N/A N/A 0.339 N/A

CD-1 Micef Females Oral 0.134 N/A N/A 0.261

Males 0.296 N/A N/A 0.263

Notes:

iv = Intravenous; N/A = Not Available; PFBA = Perfluorobutanoic Acid; PFBS = Perfluorobutane Sulfonate; PFOA =

Perfluorooctanoic Acid; PFOS = Perfluorooctane Sulfonate.

Volume of distribution (Vd) values for animals are all based on a single dose.

(a) Data from Thompson et al. (2010); calculated assuming a first-order, one-compartment model.

(b) Data from Chang et al. (2008a) for PFBA (10 mg/kg); Olsen et al. (2009) for PFBS (10 mg/kg); Butenhoff et al.

(2004a) for PFOA (10 mg/kg); and Chang et al. (2012) for PFOS (2 mg/kg).

(c) Data from Chang et al. (2008a) for PFBA (30 mg/kg); Olsen et al. (2009) for PFBS (30 mg/kg); and Chang et al.

(2012) for PFOS (2 mg/kg).

(d) Data from Kim et al. (2016) for PFOA (1 mg/kg) and PFOS (2 mg/kg).

(e) Data from Ohmori et al. (2003) for PFOA (~20 or 50 mg/kg; estimated based on administered dose reported by

Ohmori et al. as being, alternatively, 48.64 µmol/kg or 48.64 mmol/[2.5 mL/kg]; conversion based on molecular

weight of 414.069 [ATSDR, 2015]).

(f) Data from Chang et al. (2008a) for PFBA (30 mg/kg) and from Chang et al. (2012) for PFOS (20 mg/kg).

et al et al

In vitro

et al et al

in vitro

et al

5.1.2.2 Tissue Distribution

i.e

27-CV-10-28862

33


et al

27-CV-10-28862

34


Table 5.2 Tissue Distribution of PFCs By Species and Sex

Species Sex PFBA PFBS PFOA PFOS

Rats Males Serum >> Livera N/A ≤5 mg/kg

Liver >> Serum > Kidney

>> Spleen>> Brainb

≥10 mg/kg

Serum ≥ Liver ≥ Kidney >>

Spleen >> Brainb

≤0.3 mg/kg

Liver >>> Serum ≈

Kidney >> Spleen

>> Brainc

2 mg/kg

Liver >> Serum >>

Kidney >> Spleend

Females N/A N/A ≤5 mg/kg

Serum ≈ Liver ≥ Kidney >>

Spleenb

≥10 mg/kg)

Serum > Kidney > Liver >>

Spleen >>> Brainb

2 mg/kg

Liver >> Serum >>

Kidney >> Spleend

Mice Males Serum >> Livera Liver > Kidney >>

Spleen >> Braine

Liver > Serumf Liver >> Kidney >>

Spleen >> Braing

Females N/A N/A Liver >> Serumf N/A

Monkeys Males N/A N/A Serum >> Liverh Liver > Serumi

Humans N/A Kidney >>> Liver

>> Brainj

Kidney >> Liver

(ND in brain)j

Liver >> Kidney

(ND in brain)j

Kidney ≥ Liver >>>

Brainj

Notes:

CSF = Cerebral-spinal Fluid; N/A = Not Available; ND = Not Detected; PFBA = Perfluorobutanoic Acid; PFBS = Perfluorobutane

Sulfonate; PFOA = Perfluorooctanoic Acid; PFOS = Perfluorooctane Sulfonate.

≥ indicates tissue concentration is comparable or slightly greater than tissue concentration in comparison tissue.

> indicates there is a less than 2-fold difference in relative tissue concentration.

>> indicates there is a 2- to 10-fold difference in relative tissue concentration.

>>> indicates there is a greater than 10-fold difference in relative tissue concentration.

(a) Chang et al. (2008a).

(b) Data from multiple studies (summarized in Appendix Table B.1); data for PFOA levels in female rat brain at low doses are

not available.

(c) Iwabuchi et al. (2017).

(d) Kim et al. (2016).

(e) Bogdanska et al. (2014).

(f) Data from one male and one female mouse (Hundley et al., 2006).

(g) Bogdanska et al. (2011).

(h) Butenhoff et al. (2004a); evaluated only serum and liver concentrations.

(i) Seacat et al. (2002); evaluated only serum and liver concentrations.

(j) Data from 20 human cadavers (Perez et al., 2013).

27-CV-10-28862

35


Table 5.3 PFC Liver to Serum Ratiosa

Species PFBA PFOA PFOS

Rats Males

0.24 (0.22-0.27)b

Females (≤0.1 mg/kg)c

N/A

Males (≤0.1 mg/kg)c

2.4 (1.7-3.7)

Females (≥1 mg/kg)c

0.64 (0.28-0.81)

Males (≥1 mg/kg)c

0.9 (0.59-2.3)

Femalesc

2.9 (1.9-47)

Malesc

8.8 (2.6-51)

Mice Females

0.17 (0.15-0.17)d

Males

0.23 (0.21-0.28)d

Females (10 mg/kg)e

2.4

Males (10 mg/kg)e

1.6

N/A

Monkeys N/A 0.18 (3 mg/kg)f

0.13 (10 mg/kg)f

1.8 (0.9-2.2)g

Humans N/A 1.2, 3.2h 1.3i

Notes:

N/A = Not Available; PFBA = Perfluorobutanoic Acid; PFC = Perfluorinated Chemical; PFOA = Perfluorooctanoic Acid;

PFOS = Perfluorooctane Sulfonate.

(a) Values represent median and range; studies report concentrations in either serum or plasma, with values in either serum or

plasma considered equivalent. Unless otherwise specified, there was no clear dose-dependent or sex-dependent differences in

liver and serum concentrations.

(b) Data for males only (Chang et al., 2008a).

(c) Ratios based on data from multiple studies (summarized in Appendix Table B.2).

(d) Data for doses of 10-100 mg/kg (Chang et al., 2008a).

(e) Serum PFOA concentrations were estimated from whole-blood concentrations from Hundley et al. (2006) using a factor of

1.9, as estimated from data reported by Iwabuchi et al. (2017) and Kudo et al. (2007).

(f) Data from Butenhoff et al. (2004a) for males only; values represent median for n = 4 monkeys/dose.

(g) Data from Seacat et al. (2002); no apparent difference between females and males, or among doses (from 0.03-0.75 mg/kg-

day).

(h) Data available for only two cadavers (Olsen et al., 2001; also discussed in Olsen et al., 2003b).

(i) Data as reported by Olsen et al. (2003b).

et al et al et al

et

al

27-CV-10-28862

36


Table 5.4 Liver Tissue Distribution Across Species, Sex, and Dose

Comparison

Across: PFBA PFOA PFOS

Species Rats ≈ Mice Mice ≈ Humans > Rats > Monkeys Rats > Monkeys ≈ Humans

Sexes Males ≈ Females

(Mice)

Males > Females (Rats)

Females ≈ Males (Mice)

N/A (Monkeys and Humans)

Males > Females (Rats)

N/A (Mice, Monkeys, and Humans)

Doses N/A Low Dose > High Dose (Rats)

N/A (Mice, Monkeys, and Humans)

N/A

Notes:

N/A = Not Available; PFBA = Perfluorobutanoic Acid; PFOA = Perfluorooctanoic Acid; PFOS = Perfluorooctane Sulfonate.

5.1.2.3 Placental and Lactational Transfer

in utero

via

27-CV-10-28862

37


Table 5.5 Placental and Lactational Transfer

PFC Placental Transfera Lactational Transferb Offspring/Maternal Ratioc

Humans Rats Humans Rats Humans Rats

PFOA 0.79

(0.62-1.5)

0.42 0.04

(0.03-0.12)

0.10 3.0

(1.8-4.6)

0.26

PFOS 0.37

(0.29-0.56)

2.3 0.01

(0.01-0.03)

0.31 1.1

(0.93-1.4)

0.68

Notes:

PFC = Perfluorinated Chemical; PFOA = Perfluorooctanoic Acid; PFOS = Perfluorooctane Sulfonate.

Underlying data included in Appendix Table B.3.

(a) Presented as fetal (cord blood)/maternal (serum or plasma) ratio. Values for humans represent

median and range. Value for rats selected as lowest dose (as being most comparable to exposure

and sample collection in humans).

(b) Presented as breast milk/serum (or plasma) ratio. Values for humans represent median and

range. Values for rats selected as lowest dose, and at earliest time-point (as being most comparable

to exposure and sample collection in humans).

(c) Values for humans represent average of three studies, using earliest post-natal time point, based

on PFC concentrations quantified in serum or plasma. Values for rats selected as lowest dose, at

earliest post-natal time point; based on PFC concentrations quantified in either serum or plasma.

5.1.3 Metabolism

e.g.

et al

et al

5.1.4 Excretion

i.e.

e.g.

27-CV-10-28862

38


via

*> ?&@ =& A-B& × CD2Ei.e.

i.e. t1/2

e.g. e.g.

et al

et al

et al

et al

et al et al et al

vs

vs

et al

et al et al

via

vs

27-CV-10-28862

39

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ta

ble

5.6

PF

C E

lim

ina

tio

n H

alf

-liv

esa

Sp

eci

es

Se

x

PF

BA

P

FB

S

PF

OA

P

FO

S

Hu

ma

nsb

F

em

ale

s/

Ma

les

2.9

da

ys

25

.8 d

ay

s 2

.3-8

.5 y

ea

rs

3.3

-5.4

ye

ars

Mo

nk

ey

s F

em

ale

s 1

.7 d

ay

s 3

.5 d

ay

sc 3

2.6

da

ys

11

0 t

o ~

20

0 d

ay

s

Ma

les

1.7

da

ys

4.0

da

ysc

~2

0 d

ay

s 1

32

to

~2

00

da

ys

Ra

ts

Fe

ma

les

1.0

ho

urs

(iv

exp

osu

re)

1.8

ho

urs

(o

ral e

xpo

sure

)

0.6

4-7

.4 h

ou

rs

1.9

-4.6

ho

urs

(<

25

mg

/kg

)

16

.2 h

ou

rs (

25

mg

/kg

)

24

ho

urs

(5

0 m

g/k

g)

24

-83

da

ys

Ma

les

6.4

ho

urs

(iv

exp

osu

re)

9.2

ho

urs

(o

ral e

xpo

sure

)

2.1

-4.7

ho

urs

1

.6-1

5 d

ay

s (<

25

mg

/kg

)d

6.5

da

ys

(25

mg

/kg

)

4.4

da

ys

(50

mg

/kg

)

26

-82

da

yse

Mic

e

Fe

ma

les

2.9

ho

urs

(1

0 m

g/k

g)

3.1

ho

urs

(3

0 m

g/k

g)

2.8

ho

urs

(1

00

mg

/kg

)

38

da

ys

(1 m

g/k

g-d

ay

)

30

da

ys

(20

mg

/kg

-da

y)

Ma

les

13

.3 h

ou

rs (

10

mg

/kg

)

16

.3 h

ou

rs (

30

mg

/kg

)

5.2

ho

urs

(1

00

mg

/kg

)

43

da

ys

(1 m

g/k

g-d

ay

)

36

da

ys

(20

mg

/kg

-da

y)

No

tes:

iv =

In

tra

ve

no

us;

PF

BA

= P

erf

luo

rob

uta

no

ic A

cid

; P

FB

S =

Pe

rflu

oro

bu

tan

e S

ulf

on

ate

; P

FC

= P

erf

luo

rin

ate

d C

he

mic

al;

PF

OA

= P

erf

luo

roo

cta

no

ic A

cid

;

PF

OS

= P

erf

luo

roo

cta

ne

Su

lfo

na

te.

Da

ta f

or

ind

ivid

ua

l st

ud

ies

is i

ncl

ud

ed

in

Ap

pe

nd

ix T

ab

le B

.4.

(a)

Un

less

oth

erw

ise

sp

eci

fie

d,

da

ta r

ep

rese

nt

bo

th o

ral a

nd

iv e

xpo

sure

s, b

oth

acu

te a

nd

ch

ron

ic e

xpo

sure

s, a

nd

a r

an

ge

of

do

ses.

(b)

PF

BA

da

ta f

rom

Ch

an

g e

t a

l. (

20

08

a);

re

pre

sen

ts g

eo

me

tric

me

an

fo

r th

ree

em

plo

ye

es

fro

m t

he

Co

tta

ge

Gro

ve

, M

inn

eso

ta,

faci

lity

an

d n

ine

em

plo

ye

es

fro

m t

he

Co

rdo

va

, Il

lin

ois

, fa

cili

ty.

PF

BS

da

ta f

rom

Ols

en

et

al.

(2

00

9).

D

ata

fo

r P

FO

A a

nd

PF

OS

are

as

sum

ma

rize

d i

n A

pp

en

dix

Ta

ble

B.4

..

(c)

Me

an

te

rmin

al

seru

m e

lim

ina

tio

n h

alf

-lif

e (

T0

.5γ)

fo

r P

FB

S i

s fr

om

Ols

en

et

al.

(2

00

9),

est

ima

ted

usi

ng

a t

hre

e-c

om

pa

rtm

en

t m

od

el.

N

ote

th

at

Ch

en

ge

lis

et

al.

(2

00

9)

rep

ort

ed

eli

min

ati

on

ha

lf-l

ive

s o

f 8

.1 a

nd

15

ho

urs

, re

spe

ctiv

ely

, fo

r m

ale

s a

nd

fe

ma

les.

H

ow

eve

r, t

he

y m

on

ito

red

se

rum

PF

BS

con

cen

tra

tio

ns

for

on

ly 7

da

ys

vs.

31

da

ys

in O

lse

n e

t a

l. (

20

09

).

He

nce

, C

he

ng

eli

s e

t a

l. (

20

09

) m

igh

t n

ot

ha

ve

ca

ptu

red

th

e t

hir

d p

ha

se o

f e

lim

ina

tio

n

ob

serv

ed

by

Ols

en

et

al.

(2

00

9),

re

fle

cte

d i

n t

he

mu

ch l

on

ge

r h

alf

-liv

es

est

ima

ted

by

Ols

en

et

al.

(2

00

9).

(d)

Exc

lud

es

da

ta f

rom

Jo

hn

son

an

d O

be

r (1

98

0).

A

lth

ou

gh

th

e e

lim

ina

tio

n h

alf

-lif

e a

s re

po

rte

d b

y A

TS

DR

(2

01

5)

wa

s 4

.8 d

ay

s, t

he

ba

sis

for

est

ima

tin

g

the

ha

lf-l

ife

wa

s n

ot

cle

ar

fro

m t

he

un

de

rly

ing

da

ta p

rovid

ed

in

Jo

hn

son

an

d O

be

r (1

98

0).

(e)

Exc

lud

es

da

ta f

rom

Jo

hn

son

an

d O

be

r (1

97

9a

).

Alt

ho

ug

h t

he

eli

min

ati

on

ha

lf-l

ife

as

rep

ort

ed

by

AT

SD

R (

20

15

) w

as

7.5

da

ys,

th

e b

asi

s fo

r

est

ima

tin

g t

he

ha

lf-l

ife

wa

s n

ot

cle

ar

fro

m t

he

un

de

rly

ing

da

ta p

rovid

ed

in

Jo

hn

son

an

d O

be

r (1

97

9a

).

27-CV-10-28862

40


5.1.4.1 Sex Differences in Excretion

vs et al et al et al

et al et al

et al

et al vs

et al

et al

vs


vs

et al et al

et al

et al

et

al et al et al et al et al

et al et al

vs

vs

et al

et al

et al

et al

et al

27-CV-10-28862

41


et al

et al

vs

vs vs et

al

5.1.4.2 Excretion via Menstruation and Lactation

et al

via

et al

et al et al

5.1.4.3 Accounting for Interspecies Differences in Elimination Half-lives

i.e.

et al

et al

et al

2E = &CD &× &FA-B*>7?Gi.e.

27-CV-10-28862

42


5.2 Physiologically Based Pharmacokinetic (PBPK) Models

i.e.

e.g.

3H"-6,&+-&*+11(,&3)-3,-*$"*+)- = "8)(-*&3)8+-6&+-*)&*H,&*+11(,&I+"&JA))%&<A)K& L"8)(-*&A,"I+-6&*H,&*+11(,&I+"&JA))%&<A)K& L"8)(-*&A,"I+-6&%(,&*)&8,*"J)A+18

e.g.

e.g et al

et al

et al

et al et al

e.g. vs. vs.

vs

27-CV-10-28862

43


et al

et al

et al

e.g.

i.e.

et al et al et al

et al et

al

et al

et al

et

al et al et al

et al et al

27-CV-10-28862

44


5.3 PPARα Mode of Action Associated with a Species-specific Response for

PFOA

via

vs

e.g

i.e.

et al et al et

al et al

et al

et al

et al

et al

27-CV-10-28862

45


et al

et al

i.e i.e

i.e

et al et al

et al et al

vs

et al

et al

et al et al

e.g

e.g

et al

5.3.1 PPARα and PFOA Liver Effects

et al

et al

27-CV-10-28862

46


e.g et al et al

et al

e.g et al et al et al et al

et al

et al et al

et al in vitro

et al

in vitro in vivo

5.3.2 PPARα and PFOA Immunological Effects

et al

et al

i.e

vs vs

et al

et

al in vitro

vs

et al et al

27-CV-10-28862

47


et al

et al et al et al

5.3.3 PPARα and PFOA Developmental Effects

et al

Table 5.7 Comparison of Developmental Effects in Wild-type vs. PPARα-knockout Mice

Effecta Wild-type Mice PPARα-knockout Mice

Pre-natal mortality Statistically significant increase at ≥0.6

mg/kg-day.

Statistically significant increase at ≥5

mg/kg-day.

Reduced post-natal

survival

Statistically significant increase at 0.6 and 1

mg/kg-day.

No significant effect (up to 3 mg/kg-day).

Delayed eye

openingb

Trend for a delay at 0.6 mg/kg-day.

Statistically significant increase at 1 mg/kg-

day.

No significant effect up to 1 mg/kg-day.

Initial eye opening delayed by 1 day, but

mean for all pups was not significantly

different from control at 3 mg/kg-day.b

Reduced post-natal

body weight gainc

Statistically significantly reduced at 1

mg/kg-day.

No significant effect up to 3 mg/kg-day.

Notes:

PPARα-knockout Mice = Transgenic mice in which the mouse gene for peroxisome proliferator-activated receptor α is deleted.

As reported by Abbott et al. (2007).

(a) Prenatal mortality was evaluated up to 20 mg/kg-day PFOA, in both wild-type and PPARα-knockout mice; other effects were

evaluated up to 1 mg/kg-day in wild-type mice, and up to 3 mg/kg-day in PPARα-knockout mice

(b) Whereas eyes were fully opened for some of the pups on post-natal day 13 at PFOA doses of ≤1 mg/kg-day, eyes were not

fully opened for any of the pups at 3 mg/kg-day. On post-natal day 14, the percentage of pups with fully opened eyes in the 3

mg/kg-day treatment group was comparable to that in the control group.

(c) Although there was no significant effect of PFOA on body weight gain at any single dose, Abbott et al. (2007) reported there

were dose-related trends for both wild-type and PPARα-knockout mice.

et al

et al

et al

et al

vs vs

27-CV-10-28862

48


et al et al

et al

5.3.4 Implications of a PPARα Mode of Action for Minnesota's PFOA Drinking Water

Guideline

et al

et al

et al

27-CV-10-28862

49


6 Animal Studies

et al

i.e.

i.e.

et al

27-CV-10-28862

50


6.1 PFOA

6.1.1 Key Endpoints

6.1.1.1 Liver Effects

Findings in Monkeys, Rats, and Mice

i.e.

et al.

via

27-CV-10-28862

51


i.e.

et al. et al. et

al. et al.

et al.

et al

et al

i.e

et al

27-CV-10-28862

52


et al

et al

et al

et al

et al

et al

Overall Lack of Adversity of Liver Effects at Low Doses

vs

i.e

i.e i.e

27-CV-10-28862

53


et al

e.g.

e.g.

et al

et al

et al

et al

et al et al

6.1.1.2 Serum Lipid Effects

et al

et

al

et al

et al.

et al

et al

27-CV-10-28862

54


et al.

et al.

et al.

et al.

via

et al.

6.1.1.3 Thyroid Hormone-related Effects

e.g.

27-CV-10-28862

55


et al. et al.

et al.

via

et al.

6.1.1.4 Immunotoxicity Effects

in vitro

e.g.

27-CV-10-28862

56


Evaluating Immune System Effects

et al

et al

i.e.

et al

et al

et al

in

vitro

et al

in vitro

27-CV-10-28862

57


in vitro

in vitro

et al

Effects of PFOA on the Immune System

et al

et al

et al

i.e

et al

via

27-CV-10-28862

58


et al

et al via

via

i.e

et al

via

et al

et al

27-CV-10-28862

59


6.1.1.5 Developmental and Reproductive Effects

et al.

via

i.e.

i.e

et al.

et al.

et

al. et al.

et al.

et al.

et al

27-CV-10-28862

60


et al.

in utero

in utero

et al et al

et al et al

et al et al

et al et al

i.e

6.1.2 Cancer

i.e

et al

et al

et al et al

et al

et al.

et al

et al

et al.

27-CV-10-28862

61


et al

et al

via

et al

i.e

et al et al

6.1.3 Overall Conclusions for PFOA

et al

e.g et al et al

27-CV-10-28862

62


6.2 PFOS

6.2.1 Key Endpoints

i.e.

e.g.

27-CV-10-28862

63


6.2.1.1 Liver Effects

e.g.

Findings in Monkeys, Rats, and Mice

et al

et al

e.g.

i.e.

et al.

et al

via

27-CV-10-28862

64


et al.

via

et al

et al et al

et al

et al

et al

et al et al

et

al et al

Overall Lack of Adversity of Liver Effects Observed at Low Doses

et al

et al.

et al

27-CV-10-28862

65


et al

et al

i.e.

6.2.1.2 Serum Lipid Effects

et al

et al.

et al

et al

i.e.

et al.

et al

et al.

et al

et al

27-CV-10-28862

66


et al

et al et al

et al

et al

et al

et al

et al

et al

et al

et al

et al

et al

et al

et al

et al

et al

et al

et al

et al

27-CV-10-28862

67


et al

via et al

via

6.2.1.3 Thyroid Hormone-related Effects

et al.

via

et al

et al

et al

e.g.

et al

27-CV-10-28862

68


et al.

et al

et al et al

et al

et al

et al

et al et

al et al

et al

et al

et al et al

e.g. et al

et al

27-CV-10-28862

69


6.2.1.4 Immunotoxicity Effects

in vitro

e.g.

Effects of PFOS on the Immune System

via i.e. via

et al

i.e.

et al

e.g.

et al

27-CV-10-28862

70


et al.

et al

et al

et al.

et al

et al

et al et al

via via

et al

et al

vs

et al

vs

27-CV-10-28862

71


et al

et al

via vs

in vitro

et al

et

al

et al et al

et

al.

27-CV-10-28862

72


6.2.1.5 Developmental and Reproductive Effects

i.e.

e.g. et al

et al. et al

in utero

et al

et al

et al

et al

et al

e.g.

et al

et al

et al et al

et al

et al

27-CV-10-28862

73


et al

et al

i.e.

et

al

et al.

et al

et al

et al

et al

et al

et al

i.e. i.e.

et al et al

27-CV-10-28862

74


et al

i.e.

et al

6.2.2 Morbidity and Mortality

et al

et al

et al

in extremis

e.g.

et al

et al et al i.e

et al et al

et al

6.2.3 Cancer

et al

et al

e.g.

e.g.

27-CV-10-28862

75


et al

i.e.

et al

et al

et al

via

et al

et al

6.2.4 Overall Conclusions for PFOS

27-CV-10-28862

76


6.3 PFBA

6.3.1 Liver Effects

et al.

et al.

et al

et al

6.3.2 Serum Lipid Effects

et al

et al

6.3.3 Thyroid Hormone-related Effects

et al

et al

et al

27-CV-10-28862

77


6.3.4 Developmental and Reproductive Effects

et al

et al.

et al.

6.4 PFBS

et al

et al

6.4.1 Liver Effects

et al et

al

et al

6.4.2 Serum Lipid Effects

et al

27-CV-10-28862

78


6.4.3 Kidney Effects

et al

et al

6.4.4 Blood Effects

et al

et al

6.4.5 Thyroid Hormone-related Effects

et al

et al

6.4.6 Developmental and Reproductive Effects

et al

27-CV-10-28862

79


et al

6.5 Overall Conclusions for Animal Toxicity

27-CV-10-28862

80


7 Human Studies

7.1 PFOA

e.g

7.1.1 Serum Concentrations in Workers

et al

27-CV-10-28862

81


Table 7.1 Serum PFOA (ng/mL) in Representative Occupational Populations

Cohort/Population N Range Arithmetic

Mean

Geometric

Mean Reference

Male PFOA Production Workers, Italy

2000 25 1,540-86,300 18,800 11,700 Costa et al. (2009)

2001 42 730-91,900 19,700 10,200

2002 46 340-91,900 19,300 9,300

2003 41 380-74,700 13,700 6,900

2004 34 540-46,300 11,400 6,500

2006 49 540-41,900 10,800 5,800

2007 50 200-47,00 11,600 5,400

2007 (Current Exposure) 39 200-47,040 12,930

(SD: 14,430)

4,020

2007 (Former Exposure) 11 530-18,660 6,810

(SD: 6,060)

3,760

3M PFOA Production Workers (Employed between 1985-1989)

Cottage Grove, MN plant 115 ND-26,000a NR 3,300

(SD: 4,680)

Gilliland and

Mandel (1996)

Male 3M PFOA Production Workers

1993 (Cottage Grove, MN Plant) 111 ND-80,000 5,000b,c

(SD: 12,200)

1,100c,d Olsen et al. (1998)

1995 (Cottage Grove, MN Plant) 80 ND-114,100 6,800b,c

(SD: 16,000)

1,200c,d

1997 (Cottage Grove, MN Plant) 74 100-81,300 6,400b

(SD: 14,300)

1,300d Olsen et al. (2000)

2000 (Cottage Grove, MN Plant) 122 10-92,030 4,630b

(SD: 12,530)

950d Olsen and Zobel

(2007)

2000 (Antwerp, Belgium Plant) 196 10-7,040 1,020b

(SD: 1,060)

650d

2000 (Decatur, AL Plant) 188 40-12,700 1,890b

(SD: 1,610)

1,510d

2000 (All Plants Combined) 506 10-92,030 2,210b

(SD: 6,400)

1,100d

Washington Works Facility Workers, West Virginia

2004 (Current Exposure to PFOA) 259 17.4-9,500 NR 494d Sakr et al. (2007a)

2004 (Intermittent Current

Exposure to PFOA)

160 8.1-2,070 NR 176d

2004 (Past Exposure to PFOA) 264 8.6-2,590 NR 195d

2004 (No PFOA Exposure) 342 4.6-963 NR 114d

2005-2006 1881 NR 325

(SD: 920)

113d Steenland and

Winquist (2015)

C8 Health Project Cohort (2005-2006)

Worker Cohort Only 3,713 55.9-256.2e 324.6b

(SD: 920.6)

112.7d Winquist and

Steenland (2014a)

Notes:

N = Number of Participants/Samples; ND = Non-detectable; NR = Not Reported; PFOA = Perfluorooctanoic Acid; SD = Standard

Deviation.

(a) Measured total fluorine as a surrogate for PFOA, because PFOA was the primary exposure at the plant.

(b) Unclear whether an arithmetic or geometric mean; because geometric means are more common, it was assumed to be a

geometric mean (unless a median was also reported, in which case the mean value was assumed to be an arithmetic mean).

(c) Values reported in Olsen et al. (2000).

(d) Median values.

(e) 25th-75th percentile.

27-CV-10-28862

82


7.1.2 Occupational Health Studies

7.1.2.1 Reproductive and Developmental Effects

i.e

i.e

et al

et al

7.1.2.2 Liver Enzymes and Disease

et al

et al

27-CV-10-28862

83


via

et al

et al

i.e

7.1.2.3 Serum Lipids and Cardiovascular Disease

Serum Lipids and Cholesterol

et al.

et al. et al.

et al.

27-CV-10-28862

84


via

i.e i.e

et al

et al

et al

et al

vs. vs

27-CV-10-28862

85


vs.

et al

Cardiovascular Disease

et al. et al.

et al

et al

e.g

et al

27-CV-10-28862

86


et al

et al

et al

i.e

vs.

et al

i.e

27-CV-10-28862

87


7.1.2.4 Immunological Effects

et al

et al

e.g versus

et al

7.1.2.5 Kidney Effects

i.e

et al

27-CV-10-28862

88


et al

p

et al et al

et al et al et al

et al

et al

et al

7.1.2.6 Cancer

e.g et al

et al

27-CV-10-28862

89


i.e

p

et al

et al

decreased

27-CV-10-28862

90


7.1.3 Serum Concentrations in the General Population and Non-occupationally Exposed

Cohorts

vs. et al

et al

via i.e.

27-CV-10-28862

91


Table 7.2 Serum PFOA (ng/mL) in Representative Non-occupational Populations


Mean Geometric Mean Reference

NHANES 50th-95th

Percentile

1999-2000 1,562 5.20-11.9 NR 5.21 (95% CI: 4.72-5.74) CDC (2015)

Male 743 6.00-12.1 5.71 (95% CI: 5.17-6.31)

Female 819 4.70-11.3 4.80 (95% CI: 4.32-5.34)

2003-2004 2,094 4.10-9.80 3.95 (95% CI: 3.65-4.27)

Pregnant Women 76 2.6-5.6 2.39 (SE: 0.24) Woodruff et al.

(2011) Non-pregnant Women 400 3.2-8.4 3.19 (SE: 0.16)

2005-2006 2,120 4.20-11.3 3.92 (95% CI: 3.48-4.42) CDC (2015)

2007-2008 2,100 4.30-9.60 4.12 (95% CI: 4.01-4.24)

2009-2010 2,233 3.20-7.50 3.07 (95% CI: 2.81-3.36)

Male 743 6.00-12.1 3.53 (95% CI: 3.22-3.87)

Female 1,158 2.70-6.90 2.69 (95% CI: 2.45-2.96)

2011-2012 1,904 2.08-5.68 2.08 (95% CI: 1.95-2.22) CDC (2017a)

Male 966 2.38-5.62 2.37 (95% CI: 2.22-2.53)

Female 938 1.78-5.68 1.84 (95% CI: 1.68-2.01)

2013-2014 2,165 2.07-5.57 1.94 (95% CI: 1.76-2.14)

Male 1,031 2.37-5.67 2.29 (95% CI: 2.09-2.50)

Female 1,134 1.67-5.07 1.66 (95% CI: 1.48-1.87)

American Red Cross Donors 50th-95th

Percentile

2000-2001 645 4.7-12.0 NR 4.72 (95% CI: 4.52-4.93) Olsen et al.

(2017) 2006 600 3.6-7.9 3.44 (95% CI: 3.32-3.75)

2010 600 2.5-5.6 2.44 (95% CI: 2.34-2.65)

2015 616 1.1-3.2 1.08 (95% CI: 1.03-1.14)

C8 Health Project Cohort (2005-2006)a

Total Cohort

(12 to ≥60 years old)

69,025 NR 82.9 32.9 (SD: 240.8) Frisbee et al.

(2009)

Male 33,240 98.2 39.4 (SD: 284.3)

Female 35,785 68.8 27.9 (SD: 190.6)

Pregnant Women 1,845 IQR:

10.3-49.8

NR 48.8 (SD: 77.8) Stein et al.

(2009)

Children (1 to <18 years old) 12,470 NR NR 69.2 (SD: 111.9)a Frisbee et al.

(2010)

Aarhus Birth Cohort (2008-2013), Denmark


1.53-2.64

NR 2.01 Bjerregaard-

Olesen et al.

(2016)

Danish National Birth Cohort (1992-2002)

Pregnant Women

(First Trimester)

1,399 NR NR 5.6 (SD: 2.5)a Fei et al. (2007)

Pregnant Women

(Second Trimester)

200 4.5 (SD: 1.9)a

Infants (Cord blood) 50 3.7 (SD: 3.4)a

Children (Average Age: 11,

Born: 1998-2003)

973 Control

IQR:

4.00-5.42

NR 3.88-4.06b Liew et al.

(2015)

27-CV-10-28862

92




Danish Diet, Cancer, and Health Cohort (1993-1997)

Men and Women

(50-65 years old)

753 NR NR 7.1 Eriksen et al.

(2013)

Decatur Cohort 95th

Percentile

2010 153 61.1 NR 16.3 (95% CI: 13.2-19.6) Worley et al.

(2017) 2016 45 39.1 NR 11.7 (95% CI: 18.7-14.6)

Flemish Environment and Health Study (2007-2015)

2007-2011

(Infants: Cord Blood)

218 NR NR 1.51 (95% CI: 1.43-1.59) Schoeters et al.

(2017)

2012-2015


269 NR NR 1.19 (95% CI: 1.12-1.26)

Hokkaido Study on Environment and

Children's Health (2002-2005)

25th-75th

Percentile

Pregnant Women 306 0.9-2.0 1.52

(SD: 0.89)

NR Kishi et al.

(2015)

HOME Study, Cincinnati, Ohio

(2003-2006)

25th-75th

Percentile

Pregnant Women 204 3.7-7.7 NR 5.3 Braun et al.

(2016)

Taiwan Birth Panel Study (2004-2005)

Pregnant Women 429 NR NR 1.84 (SD: 2.23) Chen et al.

(2012)

Washington County, Minnesota Communities (2008)b

Men and Women

(20-86 years old)

196 1.6-177 NR 15.4 (95% CI: 13.6-17.4) Landsteiner et

al. (2014)

Men 88 NR 16.6 (95% CI: 13.9-19.8)

Women 108 14.4 (95% CI: 12.1-17.2)

Young Taiwanese Cohort Study

(2006-2008)

50th-90th

Percentile

Total (12-30 years old) 551 3.64-9.71 NR 2.67 (SD: 2.96) Lin et al.

(2013a) Men 214 NR 2.71 (SD: 2.94)

Women 337 2.64 (SD: 2.98)

12-19 years old 212 2.80 (SD: 2.90)

20-30 years old 339 2.59 (SD: 3.00)

Notes:

CI = Confidence Interval; HOME = Health Outcomes and Measures of the Environment; IQR = Interquartile Range; NHANES =

National Health and Nutrition Examination Survey; NR = Not Reported; PFOA = Perfluorooctanoic Acid.

(a) The C8 Health Project cohort includes residents of four water districts in Ohio (City of Belpre, Little Hocking Water Association,

Tuppers Plains, and Village of Pomeroy), two water districts in West Virginia (Lubeck Public Service District, and Mason County),

and some private wells in both states.

(b) Included current and former 3M workers (the authors reported that serum concentrations were not significantly different

between those who worked at 3M and those who did not [17.0 vs. 15 ng/mL, respectively]).

e.g. via

27-CV-10-28862

93


e.g.

27-CV-10-28862

94

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ta

ble

7.3

No

n-o

ccu

pa

tio

na

l P

FO

A C

oh

ort

s

Co

ho

rt

Stu

dy

Po

pu

lati

on

Lo

cati

on

P

FO

A E

xp

osu

re S

ou

rce

O

utc

om

es

Inv

est

iga

ted

C8

He

alt

h P

roje

ct C

oh

ort

O

ng

oin

g s

tud

y o

f 6

9,0

00

ad

ult

s

an

d c

hil

dre

n r

ecr

uit

ed

fro

m a

com

mu

nit

y s

urr

ou

nd

ing

a

PF

OA

pla

nt

Mid

-Oh

io V

all

ey

, U

S

Co

nta

min

ate

d d

rin

kin

g w

ate

r D

ev

elo

pm

en

tal

an

d r

ep

rod

uct

ive

,

liv

er

en

zym

es,

th

yro

id h

orm

on

es

an

d

dis

ea

se,

seru

m l

ipid

s, i

mm

un

oto

xici

ty,

kid

ne

y e

ffe

cts,

ca

nce

r

Da

nis

h N

ati

on

al

Bir

th

Co

ho

rt

10

0,0

00

pre

gn

an

t w

om

en

en

roll

ed

in

20

00

-20

02

De

nm

ark

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

foo

d,

pro

du

cts

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e

Ho

kk

aid

o B

irth

Co

ho

rt

Stu

dy

on

th

e E

nvir

on

me

nt

an

d C

hil

d's

He

alt

h

~5

00

mo

the

r-ch

ild

pa

irs

stu

die

d f

rom

20

02

-20

05

Jap

an

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

foo

d,

pro

du

cts

Imm

un

oto

xici

ty

No

rwe

gia

n M

oth

er

an

d

Ch

ild

Co

ho

rt

>9

0,0

00

pre

gn

an

t w

om

en

an

d

the

ir o

ffsp

rin

g e

nro

lle

d i

n

19

99

-20

08

No

rwa

y

Ba

ckg

rou

nd

: D

rin

kin

g w

ate

r,

foo

d,

pro

du

cts

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e,

liv

er

en

zym

es,

th

yro

id h

orm

on

es,

seru

m l

ipid

s, im

mu

no

toxi

city

, k

idn

ey

eff

ect

s

NH

AN

ES

O

ng

oin

g r

ep

rese

nta

tive

sa

mp

le

of

ge

ne

ral

US

po

pu

lati

on

US

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

foo

d,

pro

du

cts

Th

yro

id h

orm

on

es

an

d d

ise

ase

, se

rum

lip

ids

INU

EN

DO

Co

ho

rt

>3

,00

0 p

reg

na

nt

mo

the

rs a

nd

the

ir c

hil

dre

n e

nro

lle

d i

n

20

02

-20

04

Sw

ed

en

, P

ola

nd

,

Uk

rain

e,

an

d

Gre

en

lan

d

Ba

ckg

rou

nd

: D

rin

kin

g w

ate

r,

foo

d,

pro

du

cts

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e,

imm

un

oto

xici

ty

ALS

PA

C C

oh

ort

>

14

,00

0 p

reg

na

nt

wo

me

n a

nd

off

spri

ng

re

cru

ite

d i

n

19

91

-19

92

UK

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

foo

d,

pro

du

cts

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e

Od

en

se C

hil

d C

oh

ort

>

2,0

00

pre

gn

an

t w

om

en

an

d

chil

dre

n e

nro

lle

d i

n 2

01

0-2

01

2

De

nm

ark

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

foo

d,

pro

du

cts

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e,

imm

un

oto

xici

ty

CH

EF

Pro

ject

Co

ho

rt

On

go

ing

stu

dy

of

>1

,00

0

chil

dre

n b

orn

be

gin

nin

g i

n

19

86

Fa

roe

Isl

an

ds,

ha

lfw

ay

be

twe

en

No

rwa

y a

nd

Ice

lan

d

Ba

ckg

rou

nd

: D

rin

kin

g w

ate

r,

foo

d,

pro

du

cts;

die

t h

igh

in

fis

h

an

d w

ha

le m

ea

t

Imm

un

oto

xici

ty

Ta

iwa

n B

irth

Pa

ne

l S

tud

y

48

6 m

oth

er-

infa

nt

pa

irs

en

roll

ed

in

20

04

-20

05

Su

bu

rba

n a

nd

Urb

an

Ta

iwa

n

Ba

ckg

rou

nd

: D

rin

kin

g w

ate

r,

foo

d,

pro

du

cts

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e

Da

nis

h D

CH

Co

ho

rt

4,7

69

me

n a

nd

wo

me

n >

50

ye

ars

old

re

cru

ite

d 1

99

3-1

99

7

De

nm

ark

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

foo

d,

pro

du

cts

Se

rum

lip

ids

Eu

rop

ea

n Y

ou

th H

ea

rt

Su

rve

y

>1

,70

0 b

oy

s a

nd

gir

ls 9

-15

ye

ars

old

be

gin

nin

g i

n 1

99

7a

De

nm

ark

, E

sto

nia

,

No

rwa

y,

an

d P

ort

ug

al

Ba

ckg

rou

nd

: D

rin

kin

g w

ate

r,

foo

d,

pro

du

cts

Se

rum

lip

ids

No

tes:

ALS

PA

C =

Av

on

Lo

ng

itu

din

al

Stu

dy

of

Pa

ren

ts a

nd

Ch

ild

ren

; C

HE

F =

Ch

ild

ren

's H

ea

lth

an

d t

he

En

vir

on

me

nt

in t

he

Fa

roe

s; D

CH

= D

iet,

Ca

nce

r a

nd

He

alt

h;

INU

EN

DO

= B

iop

ers

iste

nt

Org

an

och

lori

ne

s in

Die

t a

nd

Hu

ma

n F

ert

ilit

y;

NH

AN

ES

= N

ati

on

al

He

alt

h a

nd

Nu

trit

ion

Exa

min

ati

on

Su

rve

y;

PF

OA

= P

erf

luo

roo

cta

no

ic A

cid

; U

K =

Un

ite

d K

ing

do

m;

US

= U

nit

ed

Sta

tes.

27-CV-10-28862

95


7.1.4 Studies in the General Population


i.e.

e.g.

Preeclampsia and Hypertension

et al


et al

et al

27-CV-10-28862

96


e.g vs.

Birth and Growth Outcomes

General Population.

et al

et al

et al

et al

et al

27-CV-10-28862

97


et al et al


e.g.

p p

p et al

et al

et al

et al

et al

Exposed Communities. et al

et al

i.e

et al

27-CV-10-28862

98


Overall Conclusions.

et al

i.e.

Timing of Puberty

in utero

et al et al et al

et al i.e.

et al

et al

p

i.e

27-CV-10-28862

99


et al et al

Conclusions for Reproductive and Developmental Effects


et al et al et al

p

p

et al

et

al et al et al et al

p

et al

27-CV-10-28862

100


et al

et al

et al

decrease

7.1.4.3 Thyroid Hormones and Disease

et al

27-CV-10-28862

101


vs

et al


Children and Adolescents

et al


et al

et al

et al

27-CV-10-28862

102


i.e

et al

Adult Populations

et al

et al

i.e

et

al

et al et al

p

27-CV-10-28862

103


et al

vs.

et al

i.e.

et

al

e.g. et

al


et al

i.e.

et al et al

increased

27-CV-10-28862

104


et al

p Haemophilus

influenzae

et al

et al

et al

et al

decreases

et al

27-CV-10-28862

105


et al

p

et al.

decreased

decreases

et al

decreases

e.g

decreased

27-CV-10-28862

106



et al

et al et al

et al

p

et al

p

et al

p

7.1.4.7 Cancer

i.e

General Population

et al

27-CV-10-28862

107


et al

et al

i.e.

et al

e.g.

p vs.

et al

et al

p

p

versus

et al

27-CV-10-28862

108


Exposed Communities

et al

p

reduction

p

e.g

i.e

e.g

7.1.5 C8 Science Panel

et al

i.e

27-CV-10-28862

109


7.1.5.1 High Cholesterol

decrease

7.1.5.2 Thyroid Disease

27-CV-10-28862

110


i.e. )

each finding in isolation was not

compelling, plausibly a result of chance or other errors

despite a lack of coherence among them

7.1.5.3 Pregnancy-induced Hypertension and Preeclampsia

et al i.e

et al

vs

et al

27-CV-10-28862

111


7.1.5.4 Ulcerative Colitis

7.1.5.5 Kidney Cancer

et al

27-CV-10-28862

112


et

al

et al

vs

i.e

vs

7.1.5.6 Testicular Cancer

et al

27-CV-10-28862

113


7.1.5.7 Overall Conclusions for C8 Science Panel

7.1.6 Overall Conclusions for Human Studies of PFOA

27-CV-10-28862

114


7.2 PFOS

e.g

i.e.

7.2.1 Serum Concentrations in Workers

27-CV-10-28862

115


i.e.

Table 7.4 Summary of 3M Occupational PFOS Serum Concentrations (ppb or ng/mL)

Plant N Range Arithmetic

Mean

Geometric

Mean Reference

Antwerp

1995 88 0-12,830a 1,930a NR Olsen et al. (1999)

1997 65 100-970a 1,480a NR

2000 196 40-6,240 950 NR Olsen and Zobel (2007)

2000 255 40-6,240 800 440 Olsen et al. (2003a)

2001 30 190-1,350 500 430 Olsen et al. (2003c)

Cottage Grove

2000 122 30-4,790 860 NR Olsen and Zobel (2007)

2002 38 50-1,170 334 254 Olsen and Mandel (2003a)

Decatur

1995 90 0-12,830a 2,440a NR Olsen et al. (1999)

1997 84 100-970a 1,960a NR

1998 (chemical plant) 126 91-10,600 NR 941 Olsen et al. (2003d)

1998 (film plant) 60 15-946 NR 136

2000 188 60-4,170 1,290 NR Olsen and Zobel (2007)

2000 263 60-10,060 1,320 910 Olsen et al. (2003a)

2002 54 82-4,258 1,621 1,008 Olsen and Mandel (2003b)

Notes:

N = Number of Participants; NR = Not Reported; ppb = Parts Per Billion.

(a) For the Antwerp and Decatur plants, combined.

(b) Baseline serum concentrations before demolition of manufacturing facility.

7.2.2 Health Endpoint Studies in Workers

i.e.

i.e.

27-CV-10-28862

116



et al

i.e.

7.2.2.2 Liver Enzymes

et al.

et al

27-CV-10-28862

117


i.e.

et al

et al

7.2.2.3 Liver Disease

i.e.

et al

et al

e.g.

7.2.2.4 Serum Lipids

et al

et al

27-CV-10-28862

118


p

p

et al

et al

p

i.e.

7.2.2.5 Cardiovascular Disease

et al.

27-CV-10-28862

119


et al

7.2.2.6 Cancer

et al et al

via

et al

27-CV-10-28862

120


et al

e.g.

e.g.

7.2.3 Serum Concentrations in the General Population and Non-occupational Exposed

Cohorts

vs. et al

et al

et al

via i.e.

27-CV-10-28862

121


Table 7.5 Serum PFOS (ng/mL) in Representative Non-occupational Populations



NHANES 50th-95th

Percentile

1999-2000 1,562 30.2-75.7 NR 30.4 (95% CI: 27.1-33.9) CDC (2015)

Male 743 34.9-78.3 33.4 (95% CI: 29.6-37.6)

Female 819 27.8-75.7 28.0 (95% CI: 24.6-31.8)

2003-2004 2,094 21.2-54.6 20.7 (95% CI: 19.2-22.3)

Pregnant Women 76 12.0-21.8 12.29 (SD: 1.02) Woodruff et al.

(2011) Non-pregnant Women 400 15.5-44.0 16.26 (SD: 0.84)

2005-2006 2,120 17.5-47.5 17.1 (95% CI: 16.0-18.2) CDC (2015)

2007-2008 2,100 13.6-40.5 13.2 (95% CI: 12.2-14.2)

2009-2010 2,233 9.70-32.0 9.32 (95% CI: 8.13-10.7)

Male 1,075 11.8-37.4 11.5 (95% CI: 9.93-13.3)

Female 819 7.80-28.8 7.65 (95% CI: 6.73-8.71)

2011-2012 1,904 6.53-21.7 6.31 (95% CI: 5.84-6.82) CDC (2017a)

Male 966 8.31-24.1 7.91 (95% CI: 7.19-8.70)

Female 938 5.27-17.5 5.10 (95% CI: 4.70-5.53)

2013-2014 2,165 5.20-18.5 4.99 (95% CI: 4.50-5.52)

Male 1,031 6.40-22.1 6.36 (95% CI: 5.62-7.20)

Female 1,134 4.00-15.1 3.96 (95% CI: 3.60-4.35)

American Red Cross Donors 50th-95th

Percentile

2000-2001 645 35.8-75.1 NR 34.9 (95% CI: 33.3-36.5) Olsen et al.

(2017) 2006 600 14.2-31.5 14.5 (95% CI: 13.9-15.2)

2010 600 8.6-21.8 8.3 (95% CI: 7.9-8.8)

2015 616 4.3-8.6 4.3 (95% CI: 4.1-4.6)

C8 Health Project Cohort (2005-2006)

Total Cohort

(12 to ≥60 years old)

66,899a NR 23.3 19.2 (SD: 15.6) Frisbee et al.

(2009)

Male 33,240 26.0 21.9 (SD: 16.5)

Female 35,785 20.7 17.0 (SD: 14.1)


9.0-17.7

NR 14.1 (SD: 7.7) Stein et al. (2009)

Children (1 to <18 years

old)

12,470 NR NR 22.8 (SD: 12.6)b Frisbee et al.

(2010)

Aarhus Birth Cohort (2008-2013)


6.0-10.7

NR 7.90 Bjerregaard-

Olesen et al.

(2016)

Danish National Birth Cohort (1992-2002)

Pregnant Women

(First Trimester)

1,399 NR NR 35.3 (SD: 13.0)b Fei et al. (2007)

Pregnant Women

(Second Trimester)

200 29.9 (SD: 11.0)b

Infants (Cord Blood) 50 11.0 (SD: 4.7)b

Children (Average Age: 11,

Born: 1998-2003)

973 Control

IQR:

27.4-35.6

NR 25.40-27.40c Liew et al. (2015)

27-CV-10-28862

122




Danish Diet, Cancer, and Health Cohort (1993-1997)

Men and Women

(50-65 years old)

753 NR NR 36.1 Eriksen et al.

(2013)

Decatur Community Cohort 95th

Percentile

2010 153 149 NR 39.8 (95% CI: 30.9-48.9) Worley et al.

(2017) 2016 45 70.6 NR 23.4 (95% CI: 18.5-28.4)

Flemish Environment and Health Study (2007-2015)

2007-2011


218 NR NR 2.66 (95% CI: 2.48-2.85) Schoeters et al.

(2017)

2012-2015


269 NR NR 1.10 (95% CI: 1.02-1.18)

Hokkaido Study (2002-2005) 25th-75th

Percentile

Pregnant Women 306 4.0-7.5 6.02

(SD: 2.67)

NR Kishi et al. (2015)

HOME Study, Cincinnati, Ohio

(2003-2006)

25th-75th

Percentile

Pregnant Women 204 9.1-18 NR 13d Braun et al.

(2016)

Taiwan Birth Panel Study (2004-2005)

Pregnant Women 429 NR NR 5.94 (SD: 1.95) Chen et al.

(2012)

Washington County, Minnesota, Communities (2008)

Men and Women

(20-86 years old)

196 3.2-448 NR 35.9 (95% CI: 32.2-40.1) Landsteiner et al.

(2014)

Men 88 NR 43.9 (95% CI: 38.1-50.7)

Women 108 30.5 (95% CI: 26.1-35.7)

Young Taiwanese Cohort Study (2006-2008)

Males 250 NR NR 8.97 (95% CI: 3.24-12.72) Lin et al. (2013b)

Females 394 7.21 (95% CI: 4.41-11.75)

12-19 years old 231 7.25 (95% CI: 2.44-23.69)

20-30 years old 413 8.21 (95% CI: 6.27-34.71)

Notes:

CI = Confidence Interval; HOME = Health Outcomes and Measures of the Environment; IQR = Interquartile Range (25th-75th

Percentile); NHANES = National Health and Nutrition Examination Survey; NR = Not Reported; SD = Standard Deviation; PFOS =

Perfluorooctane Sulfonate.

(a) Total number of participants is 69,025, but serum data were only available for 66,899 samples.

(b) Unclear whether an arithmetic or geometric mean; because geometric means are more commonly used, it was assumed that

this is a geometric mean.

(c) Depending on case or control status.

(d) The authors reported this value as the median in Supplemental Table S2, but as the geometric mean in the text.

7.2.4 Studies in the General Population

e.g. via

27-CV-10-28862

123


e.g.

27-CV-10-28862

12

4

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ta

ble

7.6

No

n-o

ccu

pa

tio

na

l P

FO

S C

oh

ort

s

Co

ho

rt

Stu

dy

Po

pu

lati

on

Lo

cati

on

P

FO

S E

xp

osu

re S

ou

rce

O

utc

om

es

Inv

est

iga

ted

C8

He

alt

h P

roje

ct C

oh

ort

6

9,0

00

ad

ult

s a

nd

ch

ild

ren

recr

uit

ed

fro

m a

co

mm

un

ity

surr

ou

nd

ing

a P

FO

A p

lan

t

Mid

-Oh

io V

all

ey

, U

S

Co

nta

min

ate

d d

rin

kin

g

wa

ter

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e,

thy

roid

ho

rmo

ne

s a

nd

dis

ea

se,

seru

m l

ipid

s, im

mu

no

toxi

city

,

kid

ne

y e

ffe

cts,

ca

nce

r

Da

nis

h N

ati

on

al

Bir

th

Co

ho

rt

10

0,0

00

pre

gn

an

t w

om

en

en

roll

ed

in 2

00

0-2

00

2

De

nm

ark

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

fo

od

, p

rod

uct

s

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e

Ho

kk

aid

o B

irth

Co

ho

rt

Stu

dy

on

th

e E

nvir

on

me

nt

an

d C

hil

d's

He

alt

h

~5

00

mo

the

r-ch

ild

pa

irs

stu

die

d

fro

m 2

00

2-2

00

5

Jap

an

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

fo

od

, p

rod

uct

s

Imm

un

oto

xici

ty

No

rwe

gia

n M

oth

er

an

d

Ch

ild

Co

ho

rt

>9

0,0

00

pre

gn

an

t w

om

en

an

d t

he

ir

off

spri

ng

en

rolle

d i

n 1

99

9-2

00

8

No

rwa

y

Ba

ckg

rou

nd

: D

rin

kin

g

wa

ter,

fo

od

, p

rod

uct

s

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e,

liv

er

en

zym

es,

th

yro

id h

orm

on

es,

seru

m l

ipid

s, im

mu

no

toxi

city

,

kid

ne

y e

ffe

cts

NH

AN

ES

O

ng

oin

g r

ep

rese

nta

tive

sa

mp

le o

f

ge

ne

ral U

S p

op

ula

tio

n

US

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

fo

od

, p

rod

uct

s

Liv

er

en

zym

es,

th

yro

id h

orm

on

es

an

d d

ise

ase

, se

rum

lip

ids

an

d C

VD

,

kid

ne

y e

ffe

cts

INU

EN

DO

Co

ho

rt

>3

,00

0 p

reg

na

nt

mo

the

rs a

nd

th

eir

chil

dre

n e

nro

lle

d i

n 2

00

2-2

00

4

Sw

ed

en

, P

ola

nd

,

Uk

rain

e,

an

d G

ree

nla

nd

Ba

ckg

rou

nd

: D

rin

kin

g

wa

ter,

fo

od

, p

rod

uct

s

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e

ALS

PA

C C

oh

ort

>

14

,00

0 p

reg

na

nt

wo

me

n a

nd

off

spri

ng

re

cru

ite

d i

n 1

99

1-1

99

2

UK

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

fo

od

, p

rod

uct

s

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e

Da

nis

h F

eta

l O

rig

ins

19

88

Co

ho

rt

96

5 p

reg

na

nt

wo

me

n (

30

we

ek

s'

ge

sta

tio

n)

en

roll

ed

in

19

88

-19

89

De

nm

ark

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

fo

od

, p

rod

uct

s

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e

Od

en

se C

hil

d C

oh

ort

>

2,0

00

pre

gn

an

t w

om

en

an

d

chil

dre

n e

nro

lle

d i

n 2

01

0-2

01

2

De

nm

ark

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

fo

od

, p

rod

uct

s

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e

CH

EF

Pro

ject

Co

ho

rt

On

go

ing

stu

dy

of

>1

,00

0 c

hil

dre

n

bo

rn b

eg

inn

ing

in

19

86

Fa

roe

Isl

an

ds,

ha

lfw

ay

be

twe

en

No

rwa

y a

nd

Ice

lan

d

Ba

ckg

rou

nd

: D

rin

kin

g

wa

ter,

fo

od

, p

rod

uct

s; d

iet

hig

h i

n f

ish

an

d w

ha

le m

ea

t

Imm

un

oto

xici

ty

Ta

iwa

n B

irth

Pa

ne

l S

tud

y

48

6 m

oth

er-

infa

nt

pa

irs

en

roll

ed

in 2

00

4-2

00

5

Su

bu

rba

n a

nd

Urb

an

Ta

iwa

n

Ba

ckg

rou

nd

: D

rin

kin

g

wa

ter,

fo

od

, p

rod

uct

s

De

ve

lop

me

nta

l a

nd

re

pro

du

ctiv

e

Da

nis

h D

CH

Co

ho

rt

4,7

69

me

n a

nd

wo

me

n

>5

0 y

ea

rs o

ld

De

nm

ark

B

ack

gro

un

d:

Dri

nk

ing

wa

ter,

fo

od

, p

rod

uct

s

Se

rum

lip

ids

27-CV-10-28862

12

5

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Co

ho

rt

Stu

dy

Po

pu

lati

on

Lo

cati

on

P

FO

S E

xp

osu

re S

ou

rce

O

utc

om

es

Inv

est

iga

ted

Eu

rop

ea

n Y

ou

th H

ea

rt

Su

rve

y

>1

,70

0 b

oy

s a

nd

gir

ls 9

-15

ye

ars

old

be

gin

nin

g i

n 1

99

7a

De

nm

ark

, E

sto

nia

,

No

rwa

y,

an

d P

ort

ug

al

Ba

ckg

rou

nd

: D

rin

kin

g

wa

ter,

fo

od

, p

rod

uct

s

Se

rum

lip

ids

Yo

un

g T

aiw

an

ese

Co

ho

rt

Stu

dy

>7

00

stu

de

nts

in

gra

de

s 1

-12

en

roll

ed

in

20

06

-20

08

Ta

iwa

n

Ba

ckg

rou

nd

: D

rin

kin

g

wa

ter,

fo

od

, p

rod

uct

s

Se

rum

lip

ids

an

d C

VD

No

tes:

ALS

PA

C =

Av

on

Lo

ng

itu

din

al

Stu

dy

of

Pa

ren

ts a

nd

Ch

ild

ren

; C

HE

F =

Ch

ild

ren

's H

ea

lth

an

d t

he

En

vir

on

me

nt

in t

he

Fa

roe

s; C

VD

= C

ard

iova

scu

lar

Dis

ea

se;

DC

H =

Die

t, C

an

cer,

an

d

He

alt

h;

INU

EN

DO

= B

iop

ers

iste

nt

Org

an

och

lori

ne

s in

Die

t a

nd

Hu

ma

n F

ert

ilit

y;

NH

AN

ES

= N

ati

on

al

He

alt

h a

nd

Nu

trit

ion

Exa

min

ati

on

Su

rve

y;

PF

OA

= P

erf

luo

roo

cta

no

ic A

cid

;

PF

OS

= P

erf

luo

roo

cta

ne

Su

lfo

na

te;

UK

= U

nit

ed

Kin

gd

om

; U

S =

Un

ite

d S

tate

s.

(a)

Th

is i

s a

n o

ng

oin

g p

rosp

ect

ive

stu

dy

; th

us,

ne

we

r st

ud

ies

(no

t d

iscu

sse

d i

n t

his

re

po

rt)

lik

ely

in

clu

de

ad

dit

ion

al

chil

dre

n r

ecr

uit

ed

aft

er

20

00

.

27-CV-10-28862

126



i.e.

e.g.

Male Fertility

et al et al et al

et al et al

et al

et al

et al et

al

et al

et al

et al

lower

p

27-CV-10-28862

127


Female Fertility


et

al

et al

et al.

versus

et al

p

et al

et al et al

et al et al

et al

et al

27-CV-10-28862

128


i.e.

Miscarriage

et al et al

et al et al et al

et al

et al

via et al

Menopause and Associated Endpoints

et al

et al et al

et al

i.e.

Preeclampsia and Pregnancy-induced Hypertension

27-CV-10-28862

129


et al

et al

et al

Birth and Growth Outcomes

et al

et al

et al

et al

et al


27-CV-10-28862

130


et al

e.g.

et al

p

p p

et al

et al et al

et al

et al

vs.

et al

et al et

al

27-CV-10-28862

131


et al

et al

i.e.

e.g et al

Congenital Anomalies

et al et al et al

et al

et al et al

et al

27-CV-10-28862

132


Neurodevelopmental Outcomes

et al

et al

et al et

al et al et al

et al

et al

Timing of Puberty

in utero

et al et al et al

et al i.e.

vs.

et al

et al

27-CV-10-28862

133


et al

et al et al

Overall Conclusions

et al


et al et al et al

et al

decrease i.e

et al

et al

decreased


27-CV-10-28862

134


et al


et al

et al

p p

et al

et al

p p

et al

et al

et al

27-CV-10-28862

135


et al

et al

et al et al

et al

et al

i.e.

27-CV-10-28862

136



Children and Adolescents

e.g.


et al

p

i.e.

et al

et al

et al

et al

Adults

et al

27-CV-10-28862

137


et al

p et al

et

al

et al

et al

i.e.

et al

e.g.

et al

et al et

al et al

et al

et al

27-CV-10-28862

138


p

et al


i.e.

et al

p Haemophilus influenzae

27-CV-10-28862

139


et al

et al

i.e.

et al et al

p

i.e

et al

i.e. et al

et al


et al et al

et al

27-CV-10-28862

140


et al

via

decreasing e.g

et al et al

i.e

et al

decreases

et al

p

et al.

27-CV-10-28862

141


decreased

decreases

et al

et al

p


et al

et al et al

et al

et al

p

27-CV-10-28862

142


et al

p

7.2.4.7 Cancer

et al

et al

et al

p

et al et al

et al

i.e.

et al

e.g. p vs.

27-CV-10-28862

143


7.2.5 Overall Conclusions for Human Studies

i.e

7.3 PFBA and PFBS

7.3.1 PFBA and PFBS Exposure

et al

et al

7.3.2 Studies in the General Population and Non-occupationally Exposed Populations


et al

27-CV-10-28862

144


et al

et al

vs


et al.

7.3.2.3 Serum Lipids

et al


et al

vs.

p

27-CV-10-28862

145


7.4 Overall Conclusions

27-CV-10-28862

146


8 Agency Guidelines

etc.

27-CV-10-28862

147


8.1 PFOA

8.1.1 US EPA

8.1.1.1 RfD

et al

et al

et al

27-CV-10-28862

148


et al

et al

8.1.1.2 Drinking Water

MN.E = ;<M& ×& ONMNPE+<,*+8,&!Q = MN.E& × &;R2

et al

MN.E&4STSSSUV86E : = STSSSSB& 86W6 X %"Y &÷ STSZ[

EW6 X %"Y

E+<,*+8,&!Q& \STSV ]6E ^ = MN.E \STSSSUV86E ^ × &;R2&4STB: ×&_`SSS&]6_&86

27-CV-10-28862

149


8.1.2 Minnesota

8.1.2.1 RfD (2008)

et al

et al

8.1.2.2 HRL

!;E = &;<M& × &;R2MNP

8.1.2.3 RfD (2017)

27-CV-10-28862

150


et al

8.1.2.4 HBV

et al

27-CV-10-28862

151


i.e

et al et al

et

al

i.e

8.1.2.5 Soil

27-CV-10-28862

152


8.2 PFOS

8.2.1 US EPA

8.2.1.1 RfD

et al

et al

i.e.

et al

et al

et al

et al

et al et al

8.2.1.2 Drinking Water

27-CV-10-28862

153


et al

MN.E&4STSSSUV86E : = STSSSSB& 86W6 X %"Y &÷ STSZ[

EW6 X %"Y

E+<,*+8,&!Q& \STSV ]6E ^ = MN.E \STSSSUV86E ^ × ;R2&4STB: × &STSSSSV[&mg7a&4rounded&to&STSSSSV&mg7a:8.2.2 Minnesota

8.2.2.1 RfD (2008)

et al

i.e.

et al.

e.g.

et al

et al

27-CV-10-28862

154


et al

et al

et al

et al

et al

et al

et al

et al

8.2.2.2 HRL

!;E = &;<M& × &;R2MNP

8.2.2.3 RfD (2017)

et al

et al

27-CV-10-28862

155


et al

et al et al et

al et al

et al

8.2.2.4 HBV

et al

i.e

vs.

27-CV-10-28862

156


et al

8.2.2.5 Soil

8.3 PFBA

8.3.1 RfD

8.3.2 Water

27-CV-10-28862

157


8.3.3 Soil

8.4 PFBS

8.4.1 US EPA

8.4.1.1 RfD

et al

27-CV-10-28862

158


via et al

8.4.1.2 Water

8.4.1.3 Soil

8.4.2 Minnesota

8.4.2.1 RfD

et al

27-CV-10-28862

159


8.4.2.2 Water

!;E = &;<M& × &;R2MNP

et al

et

al

et al

8.5 PFHxS

et al

8.6 Relative Source Contribution

et al

27-CV-10-28862

160



et al et al et

al et al et al et al et al

et al et al et al

via

8.7 Comparison of Drinking Water Guidelines to Animal Data

27-CV-10-28862

16

1

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ta

ble

8.1

C

om

pa

rati

ve

Do

ses

fro

m A

nim

al

Stu

die

s:

Nu

mb

er

of

8 o

z. G

lass

es

of

Wa

ter

at

the

Gu

ide

lin

e C

on

cen

tra

tio

ns

an

Ad

ult

Wo

uld

Ne

ed

to

Dri

nk

to

Re

ach

th

e N

OE

L o

r LO

EL

Use

d a

s th

e B

asi

s fo

r P

FC

Gu

ida

nce

Va

lue

s

No

tes:

F2

= S

eco

nd

Ge

ne

rati

on

; H

A =

Lif

eti

me

He

alt

h A

dvis

ory

; H

BV

= H

ea

lth

-ba

sed

Va

lue

; H

DL

= H

igh

-de

nsi

ty L

ipo

pro

tein

; H

ED

= H

um

an

Eq

uiv

ale

nt

Do

se;

HR

L =

He

alt

h R

isk

Lim

it;

LOE

L =

Low

est

Ob

serv

ed

Eff

ect

Le

ve

l; M

DH

= M

inn

eso

ta D

ep

art

me

nt

of

He

alt

h;

NO

EL

= N

o O

bse

rve

d E

ffe

ct L

ev

el;

PF

BA

= P

erf

luo

rob

uta

no

ic A

cid

; P

FB

S =

Pe

rflu

oro

bu

tan

e S

ulf

on

ate

; P

FC

=

Pe

rflu

ori

na

ted

Ch

em

ica

l; P

FO

A =

Pe

rflu

oro

oct

an

oic

Aci

d;

PF

OS

= P

erf

luo

roo

cta

ne

Su

lfo

na

te;

T3

= T

riio

do

thy

ron

ine

; U

S E

PA

= U

nit

ed

Sta

tes

En

vir

on

me

nta

l P

rote

ctio

n A

ge

ncy

.

(a)

As

calc

ula

ted

by

US

EP

A (

20

14

c, 2

01

6a

,b)

an

d M

DH

(2

00

8a

,b,

20

11

a,b

).

(b)

Wa

ter in

tak

e i

s ro

un

de

d t

o t

wo

sig

nif

ica

nt

dig

its.

(c)

Th

e U

S E

PA

Lif

eti

me

HA

an

d t

he

MD

H H

BV

fo

r P

FO

S a

re b

ase

d o

n p

ote

nti

al

eff

ect

s in

in

fan

ts.

An

in

fan

t a

ge

d 1

to

<2

ye

ars

we

igh

ing

11

.4 k

g (

US

EP

A,

20

11

d)

wo

uld

ha

ve

to

dri

nk

35

0 c

up

s o

f w

ate

r a

t th

e L

ife

tim

e H

A l

ev

el

an

d 9

10

cu

ps

of

wa

ter

at

the

HB

V t

o r

ea

ch t

he

NO

EL

use

d a

s th

e b

asi

s o

f th

e g

uid

an

ce.

PF

C

Stu

dy

A

ge

ncy

Gu

ida

nce

S

pe

cie

s C

riti

cal

Eff

ect

s LO

EL/

NO

EL

Do

se

(mg

/kg

-da

y)

HE

Da

(mg

/kg

-da

y)

HE

D f

or

a

70

-kg

Hu

ma

n

(mg

/da

y)

Inta

ke

of

Wa

ter

at

Gu

ide

lin

e V

alu

e N

ee

de

d

to R

ea

ch H

ED

b,c

L/D

ay

8

oz.

Gla

sse

s/

Da

y

PF

OA

La

u e

t a

l.

(20

06

)

US

EP

A

HA

Mo

use

D

ela

ye

d s

ke

leta

l

oss

ific

ati

on

, a

cce

lera

ted

ma

le p

ub

ert

y

LOE

L 1

0

.00

53

0

.37

1

5,3

00

2

2,0

00

Bu

ten

ho

ff e

t a

l.

(20

02

)

MD

H

HR

L

Mo

nk

ey

Incr

ea

sed

ab

solu

te l

ive

r

we

igh

t

LOE

L 3

0

.01

2

0.8

7

2,9

00

1

2,0

00

Lau

et

al.

(20

06

)

MD

H

HB

V

Mo

use

D

ela

ye

d s

ke

leta

l

oss

ific

ati

on

, a

cce

lera

ted

ma

le p

ub

ert

y

LOE

L 1

0

.00

53

0

.37

1

11

,00

0

45

,00

0

PF

OS

Lu

eb

ke

r e

t a

l.

(20

05

a)

US

EP

A

HA

Ra

t R

ed

uce

d w

eig

ht

ga

in i

n t

he

F2

pu

ps

NO

EL

0.1

0

.00

05

1

0.0

35

7

51

0

2,2

00

Se

aca

t e

t a

l.

(20

02

)

MD

H

HR

L

Mo

nk

ey

De

cre

ase

d H

DL

an

d T

3

NO

EL

0.1

5

0.0

03

1

0.2

17

7

20

3

,10

0

Lue

bk

er

et

al.

(20

05

a)

MD

H

HB

V

Ra

t R

ed

uce

d w

eig

ht

ga

in i

n t

he

F2

pu

ps

NO

EL

0.1

0

.00

05

1

0.0

35

7

1,3

00

5

,60

0

PF

BA

N

OT

OX

B.V

.

(20

07

a)

MD

H

HR

L

Ra

t D

ecr

ea

sed

ch

ole

ste

rol

an

d

incr

ea

sed

re

lati

ve t

hy

roid

we

igh

t

NO

EL

6.9

0

.86

6

0.2

8

,60

0

36

,00

0

PF

BS

Li

ed

er

et

al.

(20

09

a)

US

EP

A

HA

Ra

t K

idn

ey

hy

pe

rpla

sia

N

OE

L 2

00

4

8

3,3

60

8

,80

0

37

,00

0

Lie

de

r e

t a

l.

(20

09

a)

MD

H

HR

L

Ra

t D

ecr

ea

sed

he

mo

glo

bin

an

d

he

ma

tocr

it a

nd

his

tolo

gic

al

cha

ng

es

in t

he

kid

ne

y

NO

EL

60

0

.42

2

9.4

4

,20

0

18

,00

0

27-CV-10-28862

162


8.8 Minnesota's Calculation of Health Risk Indices

(XX μg PFBA/L / PFBA HBV) + (XX μg PFBS/L / PFBS HBV) + (XX μg PFHxS/L / PFHxS HBV*) +

(XX μg PFOA/L / PFOA HBV) + (XX μg PFOS/L / PFOS HBV) = Health Index

*Use PFOS HBV as the interim substitute.

et al

Rules

27-CV-10-28862

163


8.9 Characteristics of Hazardous Waste Under Minnesota Rules Part

7045.0131

27-CV-10-28862

164


27-CV-10-28862

165


9 Site Data

9.1 Data Processing and Compilation

27-CV-10-28862

16

6

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ta

ble

9.1

Su

mm

ary

of

Fil

es

Co

nta

inin

g S

am

ple

Re

sult

s

Ba

tes

Nu

mb

er

or

Fil

e N

am

e

Da

te

Re

ceiv

ed

To

tal

Nu

mb

er

of

Re

sult

s

Nu

mb

er

of

Re

sult

s b

y S

am

ple

Me

dia

Re

fere

nce

G

rou

nd

wa

ter

Su

rfa

ce

Wa

ter

Se

dim

en

t F

ish

O

the

r

Me

dia

20

17

-02

-07

_1

75

0

3/7

/20

17

8

,78

3

7,7

87

2

4

97

2

We

sto

n S

olu

tio

ns,

In

c. (

20

17

a)

20

17

-02

-07

_1

75

2

3/7

/20

17

3

,95

2

2,2

81

2

63

1

03

1,3

05

W

est

on

So

luti

on

s, I

nc.

(2

01

7b

)

20

17

-02

-07

_1

80

5

3/7

/20

17

8

,32

3

1,8

43

1

,94

4

2,1

05

2

54

2

,17

7

We

sto

n S

olu

tio

ns,

In

c. (

20

17

c)

An

cho

rQE

A_

20

17

02

07

3

/7/2

01

7

63

,87

6

63

,87

6

An

cho

r Q

EA

(2

01

7)

ST

AT

E_

02

42

46

91

4

/21

/20

17

2

3,0

10

23

,01

0

M

inn

eso

ta (

Un

da

ted

-a)

ST

AT

E_

02

47

17

58

4

/21

/20

17

6

,51

2

6,4

07

1

05

Min

ne

sota

(U

nd

ate

d-b

)

ST

AT

E_

02

49

61

19

4

/21

/20

17

3

77

3

77

M

inn

eso

ta (

Un

da

ted

-c)

ST

AT

E_

04

72

29

67

4

/28

/20

17

1

30

1

17

13

M

inn

eso

ta (

20

13

a)

ST

AT

E_

04

72

32

67

4

/28

/20

17

1

17

1

17

M

inn

eso

ta (

20

13

b)

ST

AT

E_

04

72

34

15

4

/28

/20

17

1

17

6

5

5

2

Min

ne

sota

(2

01

3c)

ST

AT

E_

04

75

29

40

4

/28

/20

17

1

82

1

82

M

inn

eso

ta (

Un

da

ted

-d)

ST

AT

E_

04

75

35

51

4

/28

/20

17

5

33

53

3

M

inn

eso

ta (

20

08

)

ST

AT

E_

02

51

26

25

5

/8/2

01

7

3,5

59

3

,55

9

Min

ne

sota

(2

00

3-2

01

1)

ST

AT

E_

05

82

62

37

5

/8/2

01

7

19

,84

7

4,6

32

3

,85

9

14

0

8,0

67

3

,14

9

Min

ne

sota

(U

nd

ate

d-e

)

Att

ach

me

ntA

1.x

lsx

6/1

5/2

01

7

24

5

24

5

MD

H (

20

17

h)

Att

ach

me

ntH

1.p

df

6/1

5/2

01

7

55

5

5

Ho

ga

n (

20

17

)

ST

AT

E_

04

74

44

48

6

/27

/20

17

7

90

79

0

W

isco

nsi

n (

20

06

-20

11

)

ST

AT

E_

04

76

76

57

6

/27

/20

17

1

4

14

M

DH

(U

nd

ate

d)

ST

AT

E_

04

78

32

03

6

/27

/20

17

1

64

1

64

M

inn

eso

ta (

20

09

-20

15

)

ST

AT

E_

05

68

17

17

6

/27

/20

17

7

7

M

inn

eso

ta (

20

12

)

ST

AT

E_

06

29

30

75

&

ST

AT

E_

04

74

35

44

6/2

7/2

01

7 &

7/1

0/2

01

7

39

9

3

99

Min

ne

sota

(2

01

1a

, U

nd

ate

d-f

)

ST

AT

E_

04

89

95

41

6

/28

/20

17

1

4

14

M

inn

eso

ta (

20

13

-20

16

)

ST

AT

E_

05

00

19

33

7

/1/2

01

7

1

1

Min

ne

sota

(2

01

1b

)

ST

AT

E_

05

07

95

53

7

/10

/20

17

1

1

W

isco

nsi

n (

20

01

-20

11

)

ST

AT

E_

05

39

57

86

7

/10

/20

17

1

1

M

inn

eso

ta (

20

05

-20

13

)

ST

AT

E_

05

46

49

28

7

/10

/20

17

2

1

21

M

inn

eso

ta (

20

05

-20

16

)

ST

AT

E_

06

26

22

14

7

/10

/20

17

7

25

72

5

M

inn

eso

ta (

19

98

-20

14

)

Sa

mp

les

wit

h w

ell

ad

vis

ori

es

sin

ce A

ug

ust

20

16

7/1

7/2

01

7

97

3

97

3

(MD

H,

20

17

i)

No

tes:

Gro

un

dw

ate

r in

clu

de

s sa

mp

les

calle

d d

rin

kin

g w

ate

r o

r g

rou

nd

wa

ter.

Oth

er

me

dia

in

clu

de

s in

ve

rte

bra

tes,

liv

er,

ra

in w

ate

r, s

torm

wa

ter,

un

kn

ow

n w

ate

r, p

ore

wa

ter,

slu

dg

e,

soil

, a

nd

so

lid

s.

27-CV-10-28862

167


§

§

§

§

§

§

§

etc

27-CV-10-28862

168


§

§

§

§ e.g

§

§

vs

9.2 Groundwater

27-CV-10-28862

��

��

��

��

Segment 1 (Assumed): Based on most direct connection from thenorthern boundary of the City of Lake Elmo to the western boundary of Washington County.

Segment 9 (Assumed): The Interrogatory cites the westernboundary as "Mississippi to the south and west." However, because Mississippi does not provide aborder to the northwestern portion of the area ofinterest, the western boundary of WashingtonCounty is assumed as the boundary for this segment.

Segment 8 (Assumed): Based on the most direct connection from theMississippi River to the western boundary ofWashington County, drawn to include the water bodiesin this area that are named in the complaint.

Segment 7 (Confirmed): Based on Interrogatory statement listing the southern boundary as "Mississippi to the south and west."

Segment 6 (Confirmed):Based on Interrogatory statementlisting the southern boundary as "Mississippi to the south and west."

Mississippi RiverFlo

w

RavineLake

East Cove

Spring Lake

Segment 5 (Assumed): The Interrogatory cites the eastern boundary as"Manning Avenue to the east." However, because the southern portion of Manning Avenue terminates at US 61/10, the eastern boundary of the City of Cottage Grove is assumed as the boundary for this segment until it meets the confirmed Interrogatory boundary of the Mississippi River.

Segment 3 (Assumed): The Interrogatory cites the eastern boundary as "Manning Avenue to the east." However, because the northern portion of Manning Avenueterminates at Stillwater Boulevard, the assumed boundary follows the eastern boundary of theCity of Lake Elmo.

Segment 2 (Confirmed): Based on Interrogatory statement listing thenorthern boundary as "Lake Elmo to the North."

Segment 4 (Confirmed): Based on Interrogatory statement listing the eastern boundary as"Manning Avenue to the east."

Pigs EyeLake

Battle Creek

Tanners Lake

Battle Creek Lake

Carver Lake

PowersLake

Goose Lake

EaglePointLake

LakeElmo

Mis

sis

sip

pi

Riv

er

SunfishLake

Raleigh Creek

Dakota County

Boundary includes Mississippi River Pools2, 3, 4, 5, 5A, and 6.

Washington County

Ramsey County

I- 94

US H

wy 61

US Hwy 10

State Hwy 36

I - 694

I- 49

4US Hwy 12

Poin

t Dougla

s D

r S

Sta

te H

wy 9

5M

an

nin

g A

ve S

Sta

te H

wy 1

20

Gen

eva A

ve

N

34th St N

State

Hwy 5

Stillwater Blvd N

40th St S

Div

isio

n S

tC

entu

ry A

ve

NN

Centu

ry A

ve

Main

St N

I- 94

Point Douglas Dr S

US

Hw

y 1

0

I- 694

US Hwy 12

34th St N

I- 4

94

Div

isio

n S

t

Oakdale Dump Site

Woodbury Disposal Area

Cottage Grove 3M Plant

Washington County Landfill

St. Paul

WoodburyAfton

Cottage Grove

Rosemount

Lake Elmo

Inver Grove Heights

Denmark Twp.

Grant

Oakdale

Hastings

Nininger Twp.

StillwaterE

agan

NewportSouth St. Paul

West Lakeland Twp.

West St. Paul

Vadnais Heights

Little Canada

Mahtomedi

St. Paul Park

White Bear Lake

Rosevill

eM

en

dota

He

ights

Sunfish Lake

Sh

ore

vie

w

Grey Cloud Island Twp.

Gem Lake

Oak Park Heights

Pin

e S

prings

Coates

Raven

na T

wp.

NOTES:1) Confirmed boundary segments are based onspecific statements detailing the boundaries of theinjuries/damages as stated in the Third SupplementalObjections and Response to Defendant 3M Company'sFirst Set of Interrogatories (Minnesota, AttorneyGeneral, 2012).2) Assumed boundary segments are assumed basedon professional judgment and consideration ofstatements in the State of Minnesota's Responses toInterrogatories.3) All site features and locations are approximate.4) The original figure was produced in color. Significantinformation will be lost if copied in black and white.

SOURCES:1) Minnesota Geospatial Commons, 2007.2) Minnesota Geospatial Commons, 2015.3) USGS, 2016a-c.4) Minnesota, Attorney General, 2012.5) ESRI, 2017a.

LEGEND

Interrogatory Boundary

Dashed = Assumed Segment

Solid = Confirmed Segment

Primary Roads

County Boundaries

�

0 1.50.75

Miles

File

Pa

th:

G:\

Pro

jects

\21

40

32

.60

_M

inn

eso

ta\G

IS\C

AD

GIS

\10

0\2

14

03

2_

10

0_

11

_B

ou

nd

ary

.mxd

9.1Interrogatory Boundary

Washington County, Minnesota

FIGURE

Date: 8/22/2017

27-CV-10-28862

��

��

��

��

Mississippi River Flow

RavineLake

East Cove

Pigs EyeLake

Battle Creek

Tanners Lake

Battle Creek Lake

Carver Lake

PowersLake

Goose Lake

EaglePointLake

LakeElmo

Mis

sis

sip

piR

ive

r

SunfishLake

Raleigh Creek

Washington County

Dakota County

Ramsey County

I- 94

US H

wy 61

US

Hw

y 1

0

I- 4

94

I- 694

US Hwy 12

Sta

te H

wy 9

5

Point Douglas Dr S

Man

nin

g A

ve S

34th St N

Gen

eva A

ve

N

State Hwy 5

Sta

te H

wy 1

20

State Hwy 36

Centu

ary

Ave

Stillwater B

lv

40th St S

Centu

ry A

ve

N

I- 49

4

I- 94

I- 694

US Hwy 12

US Hwy 61

US Hwy 10

Point Douglas Dr S

34th St N

Oakdale Dump Site

Woodbury Disposal Area

Cottage Grove 3M Plant

Washington County Landfill

NOTES:1) All site features and locations are approximate.2) The original figure was produced in color. Significantinformation will be lost if copied in black and white.

SOURCES:1) Minnesota Geospatial Commons, 2007.2) Minnesota Geospatial Commons, 2015.3) USGS, 2016a-c.4) Minnesota, Attorney General, 2012.5) Ramsey County, Minnesota, 2017.6) Weston Solutions, Inc., 2011.7) Short Elliott Hendrickson Inc., 2007.8) Minnesota Dept. of Health, 2005.9) ESRI, 2017b.

LEGEND

Fish Hatchery Dump

Cottage Grove Site

Oakdale - Abresch Dump Site

Oakdale - Brockman Dump Site

Oakdale - Eberle Dump Site

Washington County Landfill Boundary

Woodbury Site Boundary

Primary Roads

County Boundaries

�

0 10.5

Miles

File

Pa

th:

G:\

Pro

jects

\21

40

32

.60

_M

inn

eso

ta\G

IS\C

AD

GIS

\10

0\2

14

03

2_

10

0_

17

_S

ite

s.m

xd

9.2Site and Landfill Boundaries

3M PFCs, Minnesota

FIGURE

Date: 8/17/2017

��

I- 6

94

34th St NState Hwy 5 34th St N

I- 6

94

State Hwy 5Oakdale Dump Site

27-CV-10-28862

169


Table 9.2 Groundwater Location Types

Location Type Use in Groundwater Exposure Assessment?

Private Well Yes

City Well Yes

Industrial Well No, not possible drinking water

Irrigation Well No, not possible drinking water

Landfill Well No, not possible drinking water

Monitoring Well No, not possible drinking water

Non-comm. Well No, are not regularly used wells

3M Monitoring Well No, not possible drinking water

Filter Test No, not possible drinking water

Other DNR Wella No, not possible drinking water

Treatment Plant No, not possible drinking water

Test Well No, not possible drinking water

Notes:

DNR = Minnesota Department of Natural Resources.

(a) These wells belong to the DNR and are used for groundwater monitoring

(MDH, 2017j).

Past: Maximum 12-month moving average.

Current: Most-recent two sampling rounds.

9.3 Surface Water

27-CV-10-28862

170


i.e

Table 9.3 Data Availability and Generalized Data Grouping Areas for Named Water Bodies

Water Body Generalized Group Surface Water

Data

Sediment

Data

Fish

Data

Raleigh Creek Lakes Yes Yes

Battle Creek Lakes Yes Yes

Battle Creek Lake Lakes

Carver Lake Lakes Yes

Powers Lake Lakes Yes Yes

Ravine Lake Lakes Yes Yes

Pigs Eye Lake Lakes Yes

Tanners Lake Lakes Yes Yes

Sunfish Lake Lakes

Eagle Point Lake Lakes

Lake Elmo Lakes Yes Yes

Goose Lake Lakes Yes

Mississippi River East Cove Mississippi River Pool 2 Yes Yes

Mississippi River Pool 2 Mississippi River Pool 2 Yes Yes Yes



Mississippi River Pool 5 Mississippi River Pool 5/5A Yes

Mississippi River Pool 5A Mississippi River Pool 5/5A Yes

Mississippi River Pool 6 Mississippi River Pool 6

Mississippi Unknown Pool Mississippi River Yes

Notes:

No apparent data provided for: Battle Creek Lake, Sunfish Lake, Eagle Point Lake, or Mississippi River Pool 6.

The Generalized Group "Lakes" also includes the creeks that flow in and out of the lakes.

9.4 Soil

9.5 Sediment

27-CV-10-28862

171


9.6 Fish

Table 9.4 Fish Sample Types, by Water Body Type

Sample Type Lakes Mississippi River

Pool 2

Mississippi River

Pool 3

Mississippi River

Pool 4

Mississippi River

Pool 5/5A

Fillet 85 414 46 44 45

Unknown 296 52

27-CV-10-28862

172


Table 9.5 Summary of Reported Fish Data Units Basis

Water Body Fish Results Original Reported Units

(Wet/Dry Weight Basis, if Available)

Number of

Samples

Lakes µg/kg 85

Mississippi River Pool 2 ng/g

(report available confirming wet weight basis)

37

ng/g

(wet weight basis)

296

µg/kg 377

Mississippi River Pool 3 ng/g

(wet weight basis)

52

µg/kg 46

Mississippi River Pool 4 µg/kg 44

Mississippi River Pool 5/5A µg/kg 45

27-CV-10-28862

173


10 Evaluation of Site Data

10.1 Potentially Exposed Populations

via

via via

via

27-CV-10-28862

174


i.e.

via

10.2 Development of Exposure Point Concentrations

e.g

27-CV-10-28862

175


e.g.

10.3 Exposure Equations and Assumptions

10.3.1 Ingestion of PFCs in Groundwater

P-*"W, = &.b2cf &× P;cf &× .h& × .M& × hRON& × Qi

27-CV-10-28862

176


10.3.2 Ingestion of PFCs in Sediment

P-*"W, = &.b2jkDlpkqs &× & P;jkDlpkqs &× O& × .h& × .M& × hR& × 2hON& × Qi

i.e

e.g

et al

et al

et al.

27-CV-10-28862

177


10.3.3 Dermal Contact with PFCs in Sediment

P-*"W, = &.b2jkDlpkqs &× RQ& × Qh& × MQ& × hR& × .h& × .M& × 2hON& × Qi

10.3.4 Ingestion of PFCs in Surface Water

P-*"W, = &.b2vf &× P;vf &× .h& × .M& × hRON& × Qi

via

27-CV-10-28862

178


10.3.5 Ingestion of PFCs in Fish

P-*"W, = &.b2wljx &× P;wljx &× .h& × .M& × 2hON& × Qi

et al

10.4 Comparison of Exposures with the PODs Used to Set Agency Guidelines

et al

27-CV-10-28862

179


Intake

PODMOE =

10.4.1 Past Adult Female Resident's Exposures to PFCs in Private Wells

et al

i.e

et al

et al

27-CV-10-28862

180


10.4.2 Past Adult Female Resident's Exposures to PFCs in City Wells

i.e

10.4.3 Current Adult Female Resident's Exposures to PFCs in Private Wells

i.e

27-CV-10-28862

181


i.e

10.4.4 Current Adult Female Resident's Exposures to PFCs in City Wells

i.e

10.4.5 Adult Female Recreational User's Exposure to PFCs

27-CV-10-28862

182


i.e

via

et al

et al

10.5 Comparison of Resident PFC Serum Concentrations with Worker and

Animal PFC Serum Concentrations

i.e

27-CV-10-28862

183


Table 10.6 Serum Concentrations of PFOA and PFOS in Southern

Washington County Residents Compared to the US Population

PFC Year

Serum Concentrations, Geometric Means (μg/L) Fold

Increase Southern Washington

Countya GM (Range) USb GM (95% CI)

PFOA 2008 14.9 (1.6-177.0) 4.12 (4.01-4.24) 3.6

2010 11.2 (0.94-110.5) 3.07 (2.81-3.36) 3.6

2014 5.5 (0.24-47.0) 1.94 (1.76-2.14) 2.8

PFOS 2008 35.7 (3.2-448.0) 13.2 (12.2-14.2) 2.7

2010 24.9 (1.6-234.0) 9.32 (8.13-10.7) 2.7

2014 18.5 (1.0-180.0) 4.99 (4.50-5.52) 3.7

Notes:

CI = Confidence Interval; GM = Geometric Mean; PFC = Perfluorinated Chemical;

PFOA = Perfluorooctanoic Acid; PFOS = Perfluorooctane Sulfonate.

(a) Population is comprised of 149 people living in southern Washington County (MDH, 2008-

2014, 2016e).

(b) US values from CDC (2015, 2017a).

et al

et al

27-CV-10-28862

184


et al

et al


Compared to 3M Workers, MDH LOEL/NOEL, and Chang et al. (2017) Study

PFC

Serum Concentrations of PFOA and PFOS (μg/L)

Southern Washington Countya

GM (Range) 3M

Workersb

Serum Concentrations

at MDH RfD

(LOEL/NOELc)

Highest Value in

Chang et al. (2017)

Study 2008 2010 2014

PFOA 14.9

(1.6-177.0)

11.2

(0.94-110.5)

5.5

(0.24-47.0)

3,300d 38,000

(LOEL)

Not Tested

PFOS 35.7

(3.2-448.0)

24.9

(1.6-234.0)

18.5

(1.0-180.0)

2,440e 6,260

(NOEL)

165,000d

Notes:

GM = Geometric Mean; LOEL = Lowest Observed Effect Level; MDH = Minnesota Department of Health; NOEL = No Observed

Effect Level; PFC = Perfluorinated Chemical; PFOA = Perfluorooctanoic Acid; PFOS = Perfluorooctane Sulfonate; RfD = Reference

Dose.

(a) Population is comprised of 149 people living in southern Washington County (MDH, 2008-2014, 2016e).

(b) Highest serum concentrations reported in US workers. PFOA values are from Gilliland and Mandel (1996); PFOS values are

from Olsen et al. (1999).

(c) Using a more scientifically supported POD would change the PFOA LOEL to a NOEL. For PFOS, the serum concentration at

the more scientifically supported NOEL would be 25,000 μg/L (as calculated by US EPA, 2016b). The comparison to the

Minnesota population would then result in a 700-fold difference.

(d) Authors do not specify whether this is an arithmetic or geometric mean.

(e) Arithmetic mean (geometric mean not reported).

27-CV-10-28862

185


Table 10.8 Margin of Exposure Comparisons Based on Serum Concentrations in

Southern Washington County Residents

PFC

Animal

Serum POD

(μg/L)

Year

Geometric Mean 95th Percentile

Serum

Concentrations

in Residents

(μg/L)

MOEa

Serum

Concentrations

in Residents

(μg/L)

MOEa

PFOA 38,000

(LOEL)b, c

2008 14.9 2,600 60.0 630

2010 11.2 3,400 48.7 780

2014 5.5 6,900 26.0 1,500

PFOS

6,260

(NOEL)b

2008 35.7 180 100.0 63

2010 24.9 250 69.5 90

2014 18.5 340 70.0 89

25,000

(NOEL)d

2008 35.7 700 100.0 250

2010 24.9 1,000 69.5 360

2014 18.5 1,400 70.0 360

Notes:

LOEL = Lowest Observed Effect Level; MDH = Minnesota Dept. of Health; MOE = Margin of Exposure;

NOEL = No Observed Effect Level; PFC = Perfluorinated Chemical; PFOA = Perfluorooctanoic Acid;

PFOS = Perfluorooctane Sulfonate; POD = Point of Departure.

(a) MOE = POD / Serum Concentration. MOEs were rounded to two significant digits.

(b) Serum concentrations at the MDH POD.

(c) Using the more scientifically supported POD would change the PFOA LOEL to a NOEL.

(d) Based on a more scientifically supported NOEL of 0.4 mg/kg-day (see Section 8.2).

10.6 Conclusions

et al

27-CV-10-28862

186


27-CV-10-28862

18

7

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ta

ble

10

.1 S

um

ma

ry o

f H

yp

oth

eti

cal

Da

ily

In

tak

es

an

d M

arg

ins

of

Ex

po

sure

fo

r P

ast

Re

sid

en

t's

Gro

un

dw

ate

r E

xp

osu

re f

rom

Pri

va

te W

ell

s

Ex

po

sure

Are

a

Co

nst

itu

en

t

of

Po

ten

tia

l

Co

nce

rn

Gro

un

dw

ate

r

EP

C

(mg

/L)

Hy

po

the

tica

l

Da

ily

In

tak

e f

rom

Gro

un

dw

ate

r

(mg

/kg

-da

y)

Po

int

of

De

pa

rtu

re

(PO

D)

(mg

/kg

-da

y)

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Alt

ern

ati

ve

PO

D

(mg

/kg

-da

y)

Alt

ern

ati

ve

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Co

tta

ge

Gro

ve P

riva

te W

ell

s P

FO

A

0.0

01

2

0.0

00

04

3

0.0

05

3

12

0

Co

tta

ge

Gro

ve P

riva

te W

ell

s P

FO

S

0.0

00

25

0

.00

00

09

0

0.0

00

51

5

7

0.0

02

2

20

Co

tta

ge

Gro

ve P

riva

te W

ell

s P

FB

A

0.0

08

7

0.0

00

31

0

.86

2

,80

0

Co

tta

ge

Gro

ve P

riva

te W

ell

s P

FB

S

0.0

00

30

0

.00

00

11

0

.42

3

9,0

00

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

lls

PF

OA

0

.00

04

4

0.0

00

01

6

0.0

05

3

34

0

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

lls

PF

OS

0

.00

09

4

0.0

00

03

4

0.0

00

51

1

5

0.0

02

6

0

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

lls

PF

BA

0

.00

21

0

.00

00

74

0

.86

1

2,0

00

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

lls

PF

BS

0

.00

00

58

0

.00

00

02

1

0.4

2

20

0,0

00

Lak

e E

lmo

Pri

vate

We

lls

PF

OA

0

.00

30

0

.00

01

1

0.0

05

3

50

Lak

e E

lmo

Pri

vate

We

lls

PF

OS

0

.00

33

0

.00

01

2

0.0

00

51

4

.3

0.0

02

1

7

Lak

e E

lmo

Pri

vate

We

lls

PF

BA

0

.02

2

0.0

00

80

0

.86

1

,10

0

Lak

e E

lmo

Pri

vate

We

lls

PF

BS

0

.00

00

50

0

.00

00

01

8

0.4

2

24

0,0

00

Ma

ple

wo

od

Pri

vate

We

lls

PF

OA

0

.00

00

22

0

.00

00

00

77

0

.00

53

6

,90

0

Ma

ple

wo

od

Pri

vate

We

lls

PF

OS

0

.00

00

19

0

.00

00

00

68

0

.00

05

1

75

0

0.0

02

3

,00

0

Ma

ple

wo

od

Pri

vate

We

lls

PF

BA

0

.00

06

0

0.0

00

02

1

0.8

6

40

,00

0

Ma

ple

wo

od

Pri

vate

We

lls

PF

BS

0

.00

00

09

0

0.0

00

00

03

2

0.4

2

1,3

00

,00

0

Ne

wp

ort

Pri

vate

We

lls

PF

OA

0

.00

00

17

0

.00

00

00

61

0

.00

53

8

,80

0

Ne

wp

ort

Pri

vate

We

lls

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

Ne

wp

ort

Pri

vate

We

lls

PF

BA

0

.00

15

0

.00

00

54

0

.86

1

6,0

00

Ne

wp

ort

Pri

vate

We

lls

PF

BS

N

A

NA

0

.42

N

A

Oa

kd

ale

Pri

vate

We

lls

PF

OA

0

.00

08

0

0.0

00

02

8

0.0

05

3

19

0

Oa

kd

ale

Pri

vate

We

lls

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

Oa

kd

ale

Pri

vate

We

lls

PF

BA

0

.01

2

0.0

00

42

0

.86

2

,10

0

Oa

kd

ale

Pri

vate

We

lls

PF

BS

N

A

NA

0

.42

N

A

St.

Pa

ul

Pri

vate

We

lls

PF

OA

N

A

NA

0

.00

53

N

A

St.

Pa

ul

Pri

vate

We

lls

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

St.

Pa

ul

Pri

vate

We

lls

PF

BA

0

.00

06

4

0.0

00

02

3

0.8

6

38

,00

0

St.

Pa

ul

Pri

vate

We

lls

PF

BS

N

A

NA

0

.42

N

A

St.

Pa

ul

Pa

rk P

riva

te W

ell

s P

FO

A

0.0

00

09

5

0.0

00

00

34

0

.00

53

1

,60

0

St.

Pa

ul

Pa

rk P

riva

te W

ell

s P

FO

S

0.0

00

02

1

0.0

00

00

07

5

0.0

00

51

6

80

0

.00

2

2,7

00

27-CV-10-28862

18

8

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ex

po

sure

Are

a

Co

nst

itu

en

t

of

Po

ten

tia

l

Co

nce

rn

Gro

un

dw

ate

r

EP

C

(mg

/L)

Hy

po

the

tica

l

Da

ily

In

tak

e f

rom

Gro

un

dw

ate

r

(mg

/kg

-da

y)

Po

int

of

De

pa

rtu

re

(PO

D)

(mg

/kg

-da

y)

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Alt

ern

ati

ve

PO

D

(mg

/kg

-da

y)

Alt

ern

ati

ve

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

St.

Pa

ul

Pa

rk P

riva

te W

ell

s P

FB

A

0.0

01

8

0.0

00

06

4

0.8

6

13

,00

0

St.

Pa

ul

Pa

rk P

riva

te W

ell

s P

FB

S

0.0

00

00

90

0

.00

00

00

32

0

.42

1

,30

0,0

00

We

st L

ake

lan

d T

wp

Pri

vate

We

lls

PF

OA

0

.00

01

1

0.0

00

00

38

0

.00

53

1

,40

0

We

st L

ake

lan

d T

wp

Pri

vate

We

lls

PF

OS

0

.00

02

1

0.0

00

00

73

0

.00

05

1

70

0

.00

2

27

0

We

st L

ake

lan

d T

wp

Pri

vate

We

lls

PF

BA

0

.00

04

2

0.0

00

01

5

0.8

6

57

,00

0

We

st L

ake

lan

d T

wp

Pri

vate

We

lls

PF

BS

0

.00

00

01

0

0.0

00

00

00

36

0

.42

1

2,0

00

,00

0

Wo

od

bu

ry P

riva

te W

ell

s P

FO

A

0.0

00

11

0

.00

00

04

0

0.0

05

3

1,3

00

Wo

od

bu

ry P

riva

te W

ell

s P

FO

S

0.0

00

16

0

.00

00

05

7

0.0

00

51

8

9

0.0

02

3

50

Wo

od

bu

ry P

riva

te W

ell

s P

FB

A

0.0

02

3

0.0

00

08

2

0.8

6

10

,00

0

Wo

od

bu

ry P

riva

te W

ell

s P

FB

S

0.0

00

00

90

0

.00

00

00

32

0

.42

1

,30

0,0

00

No

tes:

EP

C =

Exp

osu

re P

oin

t C

on

cen

tra

tio

n;

NA

= N

ot

Ava

ila

ble

; P

FB

A =

Pe

rflu

oro

bu

tan

oic

Aci

d;

PF

BS

= P

erf

luo

rob

uta

ne

Su

lfo

na

te;

PF

OA

= P

erf

luo

roo

cta

no

ic A

cid

; P

FO

S =

Pe

rflu

oro

oct

an

e

Su

lfo

na

te.

(a)

MO

Es

we

re r

ou

nd

ed

to

tw

o s

ign

ific

an

t d

igit

s.

27-CV-10-28862

18

9

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ta

ble

10

.2 S

um

ma

ry o

f H

yp

oth

eti

cal

Da

ily

In

tak

es

an

d M

arg

ins

of

Ex

po

sure

fo

r P

ast

Re

sid

en

t's

Gro

un

dw

ate

r E

xp

osu

re f

rom

Cit

y W

ell

s

Ex

po

sure

Are

a

Co

nst

itu

en

t o

f

Po

ten

tia

l

Co

nce

rn

Gro

un

dw

ate

r

EP

C

(mg

/L)

Hy

po

the

tica

l

Da

ily

In

tak

e f

rom

Gro

un

dw

ate

r

(mg

/kg

-da

y)

Po

int

of

De

pa

rtu

re

(PO

D)

(mg

/kg

-da

y)

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Alt

ern

ati

ve

PO

D

(mg

/kg

-da

y)

Alt

ern

ati

ve

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Co

tta

ge

Gro

ve C

ity

We

lls

PF

OA

0

.00

00

40

0

.00

00

01

4

0.0

05

3

3,7

00

Co

tta

ge

Gro

ve C

ity

We

lls

PF

OS

0

.00

00

05

0

0.0

00

00

01

8

0.0

00

51

2

,90

0

0.0

02

1

1,0

00

Co

tta

ge

Gro

ve C

ity

We

lls

PF

BA

0

.00

18

0

.00

00

64

0

.86

1

3,0

00

Co

tta

ge

Gro

ve C

ity

We

lls

PF

BS

0

.00

03

0

0.0

00

01

1

0.4

2

39

,00

0

Lak

e E

lmo

Cit

y W

ell

s P

FO

A

0.0

00

20

0

.00

00

07

1

0.0

05

3

74

0

Lak

e E

lmo

Cit

y W

ell

s P

FO

S

0.0

00

20

0

.00

00

07

1

0.0

00

51

7

2

0.0

02

2

80

Lak

e E

lmo

Cit

y W

ell

s P

FB

A

0.0

01

9

0.0

00

06

8

0.8

6

13

,00

0

Lak

e E

lmo

Cit

y W

ell

s P

FB

S

0.0

00

01

2

0.0

00

00

04

3

0.4

2

98

0,0

00

Ne

wp

ort

Cit

y W

ell

s P

FO

A

0.0

00

01

0

0.0

00

00

03

6

0.0

05

3

15

,00

0

Ne

wp

ort

Cit

y W

ell

s P

FO

S

NA

N

A

0.0

00

51

N

A

0.0

02

N

A

Ne

wp

ort

Cit

y W

ell

s P

FB

A

0.0

00

70

0

.00

00

25

0

.86

3

4,0

00

Ne

wp

ort

Cit

y W

ell

s P

FB

S

NA

N

A

0.4

2

NA

Oa

kd

ale

Cit

y W

ell

s P

FO

A

0.0

00

79

0

.00

00

28

0

.00

53

1

90

Oa

kd

ale

Cit

y W

ell

s P

FO

S

0.0

01

2

0.0

00

04

2

0.0

00

51

1

2

0.0

02

4

7

Oa

kd

ale

Cit

y W

ell

s P

FB

A

0.0

02

0

0.0

00

07

1

0.8

6

12

,00

0

Oa

kd

ale

Cit

y W

ell

s P

FB

S

0.0

00

05

3

0.0

00

00

19

0

.42

2

20

,00

0

St.

Pa

ul C

ity

We

lls

PF

OA

N

A

NA

0

.00

53

N

A

St.

Pa

ul C

ity

We

lls

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

St.

Pa

ul C

ity

We

lls

PF

BA

N

A

NA

0

.86

N

A

St.

Pa

ul C

ity

We

lls

PF

BS

N

A

NA

0

.42

N

A

St.

Pa

ul

Pa

rk C

ity

We

lls

PF

OA

0

.00

00

58

0

.00

00

02

1

0.0

05

3

2,5

00

St.

Pa

ul

Pa

rk C

ity

We

lls

PF

OS

0

.00

00

07

0

0.0

00

00

02

5

0.0

00

51

2

,00

0

0.0

02

8

,00

0

St.

Pa

ul

Pa

rk C

ity

We

lls

PF

BA

0

.00

23

0

.00

00

82

0

.86

1

0,0

00

St.

Pa

ul

Pa

rk C

ity

We

lls

PF

BS

0

.00

00

06

0

0.0

00

00

02

1

0.4

2

2,0

00

,00

0

Wo

od

bu

ry C

ity W

ell

s P

FO

A

0.0

00

05

2

0.0

00

00

19

0

.00

53

2

,90

0

Wo

od

bu

ry C

ity W

ell

s P

FO

S

0.0

00

00

90

0

.00

00

00

32

0

.00

05

1

1,6

00

0

.00

2

6,2

00

Wo

od

bu

ry C

ity W

ell

s P

FB

A

0.0

00

50

0

.00

00

18

0

.86

4

8,0

00

Wo

od

bu

ry C

ity W

ell

s P

FB

S

0.0

00

01

0

0.0

00

00

03

6

0.4

2

1,2

00

,00

0

No

tes:

EP

C

=

Exp

osu

re

Po

int

Co

nce

ntr

ati

on

; N

A

=

No

t A

va

ila

ble

; P

FB

A

=

Pe

rflu

oro

bu

tan

oic

A

cid

; P

FB

S

=

Pe

rflu

oro

bu

tan

e

Su

lfo

na

te;

PF

OA

=

P

erf

luo

roo

cta

no

ic

Aci

d;

PF

OS

=

Pe

rflu

oro

oct

an

e S

ulf

on

ate

.

(a)

MO

Es

we

re r

ou

nd

ed

to

tw

o s

ign

ific

an

t d

igit

s.

27-CV-10-28862

19

0

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ta

ble

10

.3

Su

mm

ary

of

Hy

po

the

tica

l D

ail

y I

nta

ke

s a

nd

Ma

rgin

s o

f E

xp

osu

re f

or

Cu

rre

nt

(20

14

-20

17

) R

esi

de

nt'

s G

rou

nd

wa

ter

Ex

po

sure

fro

m

Pri

va

te W

ell

s w

ith

Hig

he

st E

xp

osu

re E

stim

ate

s

Ex

po

sure

Are

a

Co

nst

itu

en

t

of

Po

ten

tia

l

Co

nce

rn

Gro

un

dw

ate

r

EP

C

(mg

/L)

Hy

po

the

tica

l

Da

ily

In

tak

e

fro

m

Gro

un

dw

ate

r

(mg

/kg

-da

y)

Po

int

of

De

pa

rtu

re

(PO

D)

(mg

/kg

-da

y)

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Alt

ern

ati

ve

PO

D

(mg

/kg

-da

y)

Alt

ern

ati

ve

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Co

tta

ge

Gro

ve P

riva

te W

ell

18

29

77

P

FO

A

0.0

00

32

0

.00

00

11

0

.00

53

4

70

Co

tta

ge

Gro

ve P

riva

te W

ell

18

29

77

P

FO

S

0.0

00

18

0

.00

00

06

2

0.0

00

51

8

2

0.0

02

3

20

Co

tta

ge

Gro

ve P

riva

te W

ell

18

29

77

P

FB

A

0.0

01

4

0.0

00

05

0

0.8

6

17

,00

0

Co

tta

ge

Gro

ve P

riva

te W

ell

18

29

77

P

FB

S

0.0

00

02

4

0.0

00

00

08

5

0.4

2

49

0,0

00

Co

tta

ge

Gro

ve P

riva

te W

ell

25

73

01

P

FO

A

NA

N

A

0.0

05

3

NA

Co

tta

ge

Gro

ve P

riva

te W

ell

25

73

01

P

FO

S

NA

N

A

0.0

00

51

N

A

0.0

02

N

A

Co

tta

ge

Gro

ve P

riva

te W

ell

25

73

01

P

FB

A

0.0

04

4

0.0

00

16

0

.86

5

,50

0

Co

tta

ge

Gro

ve P

riva

te W

ell

25

73

01

P

FB

S

NA

N

A

0.4

2

NA

Co

tta

ge

Gro

ve P

riva

te W

ell

25

73

34

P

FO

A

0.0

00

90

0

.00

00

32

0

.00

53

1

70

Co

tta

ge

Gro

ve P

riva

te W

ell

25

73

34

P

FO

S

0.0

00

02

6

0.0

00

00

09

1

0.0

00

51

5

60

0

.00

2

2,2

00

Co

tta

ge

Gro

ve P

riva

te W

ell

25

73

34

P

FB

A

0.0

00

56

0

.00

00

20

0

.86

4

4,0

00

Co

tta

ge

Gro

ve P

riva

te W

ell

25

73

34

P

FB

S

0.0

00

02

0

0.0

00

00

06

9

0.4

2

60

0,0

00

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

ll 2

57

69

3

PF

OA

0

.00

00

34

0

.00

00

01

2

0.0

05

3

4,4

00

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

ll 2

57

69

3

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

ll 2

57

69

3

PF

BA

0

.00

08

2

0.0

00

02

9

0.8

6

29

,00

0

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

ll 2

57

69

3

PF

BS

0

.00

00

68

0

.00

00

02

4

0.4

2

17

0,0

00

Gre

y C

lou

d I

sla

nd

Tw

p P

riva

te W

ell

25

76

94

P

FO

A

0.0

00

35

0

.00

00

12

0

.00

53

4

30

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

ll 2

57

69

4

PF

OS

0

.00

04

7

0.0

00

01

7

0.0

00

51

3

1

0.0

02

1

20

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

ll 2

57

69

4

PF

BA

0

.00

08

1

0.0

00

02

9

0.8

6

30

,00

0

Gre

y C

lou

d I

sla

nd

Tw

p P

riv

ate

We

ll 2

57

69

4

PF

BS

0

.00

00

31

0

.00

00

01

1

0.4

2

39

0,0

00

Lak

e E

lmo

Pri

vate

We

ll 1

51

70

3

PF

OA

0

.00

02

6

0.0

00

00

93

0

.00

53

5

70

Lak

e E

lmo

Pri

vate

We

ll 1

51

70

3

PF

OS

0

.00

00

28

0

.00

00

01

00

0

.00

05

1

51

0

0.0

02

2

,00

0

Lak

e E

lmo

Pri

vate

We

ll 1

51

70

3

PF

BA

0

.00

48

0

.00

01

7

0.8

6

5,0

00

Lak

e E

lmo

Pri

vate

We

ll 1

51

70

3

PF

BS

N

A

NA

0

.42

N

A

Lak

e E

lmo

Pri

vate

We

ll 7

30

40

3

PF

OA

0

.00

05

8

0.0

00

02

0

0.0

05

3

26

0

Lak

e E

lmo

Pri

vate

We

ll 7

30

40

3

PF

OS

0

.00

04

0

0.0

00

01

4

0.0

00

51

3

6

0.0

02

1

40

Lak

e E

lmo

Pri

vate

We

ll 7

30

40

3

PF

BA

0

.00

19

0

.00

00

66

0

.86

1

3,0

00

Lak

e E

lmo

Pri

vate

We

ll 7

30

40

3

PF

BS

0

.00

00

41

0

.00

00

01

4

0.4

2

29

0,0

00

27-CV-10-28862

19

1

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ex

po

sure

Are

a

Co

nst

itu

en

t

of

Po

ten

tia

l

Co

nce

rn

Gro

un

dw

ate

r

EP

C

(mg

/L)

Hy

po

the

tica

l

Da

ily

In

tak

e

fro

m

Gro

un

dw

ate

r

(mg

/kg

-da

y)

Po

int

of

De

pa

rtu

re

(PO

D)

(mg

/kg

-da

y)

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Alt

ern

ati

ve

PO

D

(mg

/kg

-da

y)

Alt

ern

ati

ve

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Lak

e E

lmo

Pri

vate

We

ll 7

30

66

3

PF

OA

0

.00

05

1

0.0

00

01

8

0.0

05

3

29

0

Lak

e E

lmo

Pri

vate

We

ll 7

30

66

3

PF

OS

0

.00

04

2

0.0

00

01

5

0.0

00

51

3

4

0.0

02

1

30

Lak

e E

lmo

Pri

vate

We

ll 7

30

66

3

PF

BA

0

.00

19

0

.00

00

68

0

.86

1

3,0

00

Lak

e E

lmo

Pri

vate

We

ll 7

30

66

3

PF

BS

0

.00

00

39

0

.00

00

01

4

0.4

2

30

0,0

00

Ma

ple

wo

od

Pri

vate

We

ll 1

22

01

9

PF

OA

0

.00

00

13

0

.00

00

00

45

0

.00

53

1

2,0

00

Ma

ple

wo

od

Pri

vate

We

ll 1

22

01

9

PF

OS

0

.00

00

35

0

.00

00

01

2

0.0

00

51

4

20

0

.00

2

1,6

00

Ma

ple

wo

od

Pri

vate

We

ll 1

22

01

9

PF

BA

0

.00

02

6

0.0

00

00

91

0

.86

9

5,0

00

Ma

ple

wo

od

Pri

vate

We

ll 1

22

01

9

PF

BS

0

.00

00

30

0

.00

00

01

1

0.4

2

40

0,0

00

Ma

ple

wo

od

Pri

vate

We

ll 4

27

87

2

PF

OA

0

.00

00

14

0

.00

00

00

51

0

.00

53

1

0,0

00

Ma

ple

wo

od

Pri

vate

We

ll 4

27

87

2

PF

OS

0

.00

00

34

0

.00

00

01

2

0.0

00

51

4

20

0

.00

2

1,6

00

Ma

ple

wo

od

Pri

vate

We

ll 4

27

87

2

PF

BA

0

.00

03

9

0.0

00

01

4

0.8

6

63

,00

0

Ma

ple

wo

od

Pri

vate

We

ll 4

27

87

2

PF

BS

N

A

NA

0

.42

N

A

Ne

wp

ort

Pri

vate

We

ll 4

43

91

0

PF

OA

0

.00

00

29

0

.00

00

01

0

0.0

05

3

5,1

00

Ne

wp

ort

Pri

vate

We

ll 4

43

91

0

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

Ne

wp

ort

Pri

vate

We

ll 4

43

91

0

PF

BA

0

.00

07

6

0.0

00

02

7

0.8

6

32

,00

0

Ne

wp

ort

Pri

vate

We

ll 4

43

91

0

PF

BS

N

A

NA

0

.42

N

A

Ne

wp

ort

Pri

vate

We

ll 5

51

00

0

PF

OA

N

A

NA

0

.00

53

N

A

Ne

wp

ort

Pri

vate

We

ll 5

51

00

0

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

Ne

wp

ort

Pri

vate

We

ll 5

51

00

0

PF

BA

0

.00

01

9

0.0

00

00

68

0

.86

1

30

,00

0

Ne

wp

ort

Pri

vate

We

ll 5

51

00

0

PF

BS

N

A

NA

0

.42

N

A

St.

Pa

ul

Pri

vate

We

ll 2

74

36

0

PF

OA

N

A

NA

0

.00

53

N

A

St.

Pa

ul

Pri

vate

We

ll 2

74

36

0

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

St.

Pa

ul

Pri

vate

We

ll 2

74

36

0

PF

BA

0

.00

03

5

0.0

00

01

2

0.8

6

69

,00

0

St.

Pa

ul

Pri

vate

We

ll 2

74

36

0

PF

BS

N

A

NA

0

.42

N

A

St.

Pa

ul

Pa

rk P

riva

te W

ell

25

78

49

P

FO

A

NA

N

A

0.0

05

3

NA

St.

Pa

ul

Pa

rk P

riva

te W

ell

25

78

49

P

FO

S

NA

N

A

0.0

00

51

N

A

0.0

02

N

A

St.

Pa

ul

Pa

rk P

riva

te W

ell

25

78

49

P

FB

A

0.0

01

6

0.0

00

05

5

0.8

6

16

,00

0

St.

Pa

ul

Pa

rk P

riva

te W

ell

25

78

49

P

FB

S

NA

N

A

0.4

2

NA

27-CV-10-28862

19

2

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ex

po

sure

Are

a

Co

nst

itu

en

t

of

Po

ten

tia

l

Co

nce

rn

Gro

un

dw

ate

r

EP

C

(mg

/L)

Hy

po

the

tica

l

Da

ily

In

tak

e

fro

m

Gro

un

dw

ate

r

(mg

/kg

-da

y)

Po

int

of

De

pa

rtu

re

(PO

D)

(mg

/kg

-da

y)

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Alt

ern

ati

ve

PO

D

(mg

/kg

-da

y)

Alt

ern

ati

ve

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

57

20

5

PF

OA

0

.00

01

0

0.0

00

00

36

0

.00

53

1

,50

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

57

20

5

PF

OS

0

.00

00

65

0

.00

00

02

3

0.0

00

51

2

20

0

.00

2

86

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

57

20

5

PF

BA

0

.00

04

2

0.0

00

01

5

0.8

6

57

,00

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

57

20

5

PF

BS

N

A

NA

0

.42

N

A

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

1

PF

OA

0

.00

00

13

0

.00

00

00

45

0

.00

53

1

2,0

00

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

1

PF

OS

0

.00

00

15

0

.00

00

00

53

0

.00

05

1

95

0

0.0

02

3

,70

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

1

PF

BA

0

.00

02

0

0.0

00

00

69

0

.86

1

20

,00

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

1

PF

BS

0

.00

00

26

0

.00

00

00

91

0

.42

4

60

,00

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

2

PF

OA

0

.00

00

56

0

.00

00

02

0

0.0

05

3

2,7

00

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

2

PF

OS

0

.00

00

31

0

.00

00

01

1

0.0

00

51

4

60

0

.00

2

1,8

00

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

2

PF

BA

0

.00

03

1

0.0

00

01

1

0.8

6

78

,00

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

2

PF

BS

N

A

NA

0

.42

N

A

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

3

PF

OA

0

.00

00

57

0

.00

00

02

0

0.0

05

3

2,6

00

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

3

PF

OS

0

.00

00

53

0

.00

00

01

9

0.0

00

51

2

70

0

.00

2

1,1

00

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

3

PF

BA

0

.00

02

9

0.0

00

01

0

0.8

6

83

,00

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

3

PF

BS

N

A

NA

0

.42

N

A

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

4

PF

OA

N

A

NA

0

.00

53

N

A

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

4

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

4

PF

BA

0

.00

00

69

0

.00

00

02

4

0.8

6

35

0,0

00

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 2

74

30

4

PF

BS

N

A

NA

0

.42

N

A

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 4

09

67

2

PF

OA

N

A

NA

0

.00

53

N

A

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 4

09

67

2

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 4

09

67

2

PF

BA

0

.00

02

3

0.0

00

00

82

0

.86

1

00

,00

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 4

09

67

2

PF

BS

0

.00

00

03

0

0.0

00

00

01

1

0.4

2

3,9

00

,00

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 4

27

89

8

PF

OA

0

.00

01

1

0.0

00

00

38

0

.00

53

1

,40

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 4

27

89

8

PF

OS

0

.00

02

1

0.0

00

00

73

0

.00

05

1

70

0

.00

2

27

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 4

27

89

8

PF

BA

0

.00

03

3

0.0

00

01

2

0.8

6

74

,00

0

We

st L

ake

lan

d T

wp

Pri

vate

We

ll 4

27

89

8

PF

BS

N

A

NA

0

.42

N

A

Wo

od

bu

ry P

riva

te W

ell

25

72

41

P

FO

A

0.0

00

06

3

0.0

00

00

22

0

.00

53

2

,40

0

Wo

od

bu

ry P

riva

te W

ell

25

72

41

P

FO

S

0.0

00

09

3

0.0

00

00

33

0

.00

05

1

15

0

0.0

02

6

00

Wo

od

bu

ry P

riva

te W

ell

25

72

41

P

FB

A

0.0

00

28

0

.00

00

09

8

0.8

6

87

,00

0

Wo

od

bu

ry P

riva

te W

ell

25

72

41

P

FB

S

NA

N

A

0.4

2

NA

27-CV-10-28862

19

3

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ex

po

sure

Are

a

Co

nst

itu

en

t

of

Po

ten

tia

l

Co

nce

rn

Gro

un

dw

ate

r

EP

C

(mg

/L)

Hy

po

the

tica

l

Da

ily

In

tak

e

fro

m

Gro

un

dw

ate

r

(mg

/kg

-da

y)

Po

int

of

De

pa

rtu

re

(PO

D)

(mg

/kg

-da

y)

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Alt

ern

ati

ve

PO

D

(mg

/kg

-da

y)

Alt

ern

ati

ve

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Wo

od

bu

ry P

riva

te W

ell

50

77

76

P

FO

A

NA

N

A

0.0

05

3

NA

Wo

od

bu

ry P

riva

te W

ell

50

77

76

P

FO

S

NA

N

A

0.0

00

51

N

A

0.0

02

N

A

Wo

od

bu

ry P

riva

te W

ell

50

77

76

P

FB

A

0.0

01

2

0.0

00

04

3

0.8

6

20

,00

0

Wo

od

bu

ry P

riva

te W

ell

50

77

76

P

FB

S

NA

N

A

0.4

2

NA

No

tes:

EP

C =

Exp

osu

re P

oin

t C

on

cen

tra

tio

n;

NA

= N

ot

Ava

ila

ble

; P

FB

A =

Pe

rflu

oro

bu

tan

oic

Aci

d;

PF

BS

= P

erf

luo

rob

uta

ne

Su

lfo

na

te;

PF

OA

= P

erf

luo

roo

cta

no

ic A

cid

; P

FO

S =

Pe

rflu

oro

oct

an

e

Su

lfo

na

te.

Fo

r p

riv

ate

we

lls,

PF

C c

on

cen

tra

tio

ns

are

ave

rag

ed

in

div

idu

all

y b

y w

ell

, a

s d

iscu

sse

d i

n S

ect

ion

10

.2.

Th

e e

xpo

sure

an

aly

sis

wa

s p

erf

orm

ed

fo

r 7

36

in

div

idu

al

pri

va

te w

ell

s in

wh

ich

PF

Cs

we

re d

ete

cte

d.

Exp

osu

re e

stim

ate

s a

nd

MO

Es

are

dis

pla

ye

d i

n t

he

ta

ble

ab

ove

fo

r w

ell

s th

at

ha

d t

he

hig

he

st e

xpo

sure

est

ima

tes

for

PF

OA

or

PF

OS

or

the

lo

we

st o

ve

rall

MO

Es.

(a)

MO

Es

we

re r

ou

nd

ed

to

tw

o s

ign

ific

an

t d

igit

s.

27-CV-10-28862

19

4

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ta

ble

10

.4

Su

mm

ary

of

Hy

po

the

tica

l D

ail

y I

nta

ke

s a

nd

Ma

rgin

s o

f E

xp

osu

re f

or

Cu

rre

nt

(20

14

-20

17

) R

esi

de

nt'

s G

rou

nd

wa

ter

Ex

po

sure

fro

m

Cit

y W

ell

s

Ex

po

sure

Are

a

Co

nst

itu

en

t

of

Po

ten

tia

l

Co

nce

rn

Gro

un

dw

ate

r

EP

C

(mg

/L)

Hy

po

the

tica

l D

ail

y

Inta

ke

fro

m

Gro

un

dw

ate

r

(mg

/kg

-da

y)

Po

int

of

De

pa

rtu

re

(PO

D)

(mg

/kg

-da

y)

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Alt

ern

ati

ve

PO

D

(mg

/kg

-da

y)

Alt

ern

ati

ve

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Co

tta

ge

Gro

ve C

ity

We

lls

PF

OA

0

.00

00

29

0

.00

00

01

0

0.0

05

3

5,2

00

Co

tta

ge

Gro

ve C

ity

We

lls

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

Co

tta

ge

Gro

ve C

ity

We

lls

PF

BA

0

.00

07

2

0.0

00

02

6

0.8

6

33

,00

0

Co

tta

ge

Gro

ve C

ity

We

lls

PF

BS

0

.00

00

53

0

.00

00

01

9

0.4

2

22

0,0

00

Lak

e E

lmo

Cit

y W

ell

s P

FO

A

0.0

00

04

6

0.0

00

00

16

0

.00

53

3

,20

0

Lak

e E

lmo

Cit

y W

ell

s P

FO

S

NA

N

A

0.0

00

51

N

A

0.0

02

N

A

Lak

e E

lmo

Cit

y W

ell

s P

FB

A

0.0

00

22

0

.00

00

07

7

0.8

6

11

0,0

00

Lak

e E

lmo

Cit

y W

ell

s P

FB

S

NA

N

A

0.4

2

NA

Ne

wp

ort

Cit

y W

ell

s P

FO

A

NA

N

A

0.0

05

3

NA

Ne

wp

ort

Cit

y W

ell

s P

FO

S

NA

N

A

0.0

00

51

N

A

0.0

02

N

A

Ne

wp

ort

Cit

y W

ell

s P

FB

A

0.0

00

33

0

.00

00

12

0

.86

7

3,0

00

Ne

wp

ort

Cit

y W

ell

s P

FB

S

NA

N

A

0.4

2

NA

Oa

kd

ale

Cit

y W

ell

s P

FO

A

0.0

00

14

0

.00

00

05

1

0.0

05

3

1,0

00

Oa

kd

ale

Cit

y W

ell

s P

FO

S

0.0

00

17

0

.00

00

06

1

0.0

00

51

8

3

0.0

02

3

30

Oa

kd

ale

Cit

y W

ell

s P

FB

A

0.0

00

40

0

.00

00

14

0

.86

6

1,0

00

Oa

kd

ale

Cit

y W

ell

s P

FB

S

0.0

00

03

7

0.0

00

00

13

0

.42

3

20

,00

0

St.

Pa

ul

Pa

rk C

ity

We

lls

PF

OA

0

.00

00

24

0

.00

00

00

86

0

.00

53

6

,20

0

St.

Pa

ul

Pa

rk C

ity

We

lls

PF

OS

N

A

NA

0

.00

05

1

NA

0

.00

2

NA

St.

Pa

ul

Pa

rk C

ity

We

lls

PF

BA

0

.00

12

0

.00

00

41

0

.86

2

1,0

00

St.

Pa

ul

Pa

rk C

ity

We

lls

PF

BS

0

.00

00

20

0

.00

00

00

72

0

.42

5

80

,00

0

Wo

od

bu

ry C

ity W

ell

s P

FO

A

0.0

00

03

4

0.0

00

00

12

0

.00

53

4

,30

0

Wo

od

bu

ry C

ity W

ell

s P

FO

S

0.0

00

03

6

0.0

00

00

13

0

.00

05

1

39

0

0.0

02

1

,50

0

Wo

od

bu

ry C

ity W

ell

s P

FB

A

0.0

00

23

0

.00

00

08

3

0.8

6

10

0,0

00

Wo

od

bu

ry C

ity W

ell

s P

FB

S

0.0

00

04

8

0.0

00

00

17

0

.42

2

50

,00

0

No

tes:

EP

C =

E

xpo

sure

Po

int

Co

nce

ntr

ati

on

; N

A =

N

ot

Ava

ila

ble

; P

FO

A =

P

erf

luo

roo

cta

no

ic A

cid

; P

FB

A =

P

erf

luo

rob

uta

no

ic A

cid

; P

FB

S =

P

erf

luo

rob

uta

ne

S

ulf

on

ate

; P

FO

S =

Pe

rflu

oro

oct

an

e S

ulf

on

ate

.

Fo

r ci

ty w

ell

s, P

FC

co

nce

ntr

ati

on

s a

re a

ve

rag

ed

in

div

idu

all

y b

y w

ell

an

d t

he

n a

ve

rag

ed

to

ge

the

r to

pro

vid

e a

n a

ve

rag

e e

xpo

sure

to

cit

y w

ell

wa

ter

ba

sed

on

th

e a

ssu

mp

tio

n

tha

t w

ate

r is

eq

ua

lly

dis

trib

ute

d b

etw

ee

n t

he

we

lls.

(a)

MO

Es

we

re r

ou

nd

ed

to

tw

o s

ign

ific

an

t d

igit

s.

27-CV-10-28862

19

5

\\ca

mfs

\G_

Dri

ve

\Pro

ject

s\2

14

03

2.6

0_

Min

ne

sota

\Te

xtP

roc\

r11

03

17

a.d

ocx

Ta

ble

10

.5 S

um

ma

ry o

f H

yp

oth

eti

cal

Da

ily

In

tak

es

an

d M

arg

ins

of

Ex

po

sure

fo

r P

ast

an

d C

urr

en

t R

ecr

ea

tio

na

l U

ser

Ex

po

sure

Are

a

Co

nst

itu

en

t o

f

Po

ten

tia

l

Co

nce

rn

Re

cre

ati

on

al

Use

r

Hy

po

the

tica

l

Da

ily

In

tak

e,

No

n-c

an

cer

(mg

/kg

-da

y)

Po

int

of

De

pa

rtu

re

(PO

D)

(mg

/kg

-da

y)

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Alt

ern

ati

ve

PO

D

(mg

/kg

-da

y)

Alt

ern

ati

ve

Ma

rgin

of

Ex

po

sure

(MO

E =

PO

D/

Da

ily

In

tak

e)a

Lak

es

PF

OA

0

.00

00

01

7

0.0

05

3

3,2

00

Lak

es

PF

OS

0

.00

01

1

0.0

00

51

4

.6

0.0

02

1

8

Lak

es

PF

BA

0

.00

00

00

03

9

0.8

6

22

,00

0,0

00

Lak

es

PF

BS

0

.00

00

00

00

09

9

0.4

2

42

0,0

00

,00

0

Mis

siss

ipp

i R

ive

r P

oo

l 2

P

FO

A

0.0

00

00

04

7

0.0

05

3

11

,00

0

Mis

siss

ipp

i R

ive

r P

oo

l 2

P

FO

S

0.0

00

09

0

0.0

00

51

5

.7

0.0

02

2

2

Mis

siss

ipp

i R

ive

r P

oo

l 2

P

FB

A

0.0

00

00

03

5

0.8

6

2,4

00

,00

0

Mis

siss

ipp

i R

ive

r P

oo

l 2

P

FB

S

0.0

00

00

02

8

0.4

2

1,5

00

,00

0

Mis

siss

ipp

i R

ive

r P

oo

l 3

P

FO

A

0.0

00

00

00

01

4

0.0

05

3

3,8

00

,00

0

Mis

siss

ipp

i R

ive

r P

oo

l 3

P

FO

S

0.0

00

03

5

0.0

00

51

1

4

0.0

02

5

7

Mis

siss

ipp

i R

ive

r P

oo

l 3

P

FB

A

0.0

00

00

00

06

7

0.8

6

13

0,0

00

,00

0

Mis

siss

ipp

i R

ive

r P

oo

l 3

P

FB

S

0.0

00

00

00

02

0

0.4

2

22

0,0

00

,00

0

Mis

siss

ipp

i R

ive

r P

oo

l 4

P

FO

A

0.0

00

00

00

02

7

0.0

05

3

1,9

00

,00

0

Mis

siss

ipp

i R

ive

r P

oo

l 4

P

FO

S

0.0

00

03

4

0.0

00

51

1

5

0.0

02

6

0

Mis

siss

ipp

i R

ive

r P

oo

l 4

P

FB

A

0.0

00

00

00

02

3

0.8

6

37

0,0

00

,00

0

Mis

siss

ipp

i R

ive

r P

oo

l 4

P

FB

S

All

ND

0

.42

A

ll N

D

Mis

siss

ipp

i R

ive

r P

oo

l 5

/5A

P

FO

A

All

ND

0

.00

53

A

ll N

D

Mis

siss

ipp

i R

ive

r P

oo

l 5

/5A

P

FO

S

0.0

00

03

5

0.0

00

51

1

5

0.0

02

5

7

Mis

siss

ipp

i R

ive

r P

oo

l 5

/5A

P

FB

A

All

ND

0

.86

A

ll N

D

Mis

siss

ipp

i R

ive

r P

oo

l 5

/5A

P

FB

S

All

ND

0

.42

A

ll N

D

No

tes:

ND

= N

ot

De

tect

ed

; P

FB

A =

Pe

rflu

oro

bu

tan

oic

Aci

d;

PF

BS

= P

erf

luo

rob

uta

ne

Su

lfo

na

te;

PF

OA

= P

erf

luo

roo

cta

no

ic A

cid

; P

FO

S =

Pe

rflu

oro

oct

an

e S

ulf

on

ate

.

(a)

MO

Es

we

re r

ou

nd

ed

to

tw

o s

ign

ific

an

t d

igit

s.

27-CV-10-28862

196


11 Development of Scientific Knowledge of PFC

Toxicity Over Time

11.1 Introduction

e.g

et al

et al

et

al

11.1.1 Analytical Methodology

e.g.

e.g. e.g.

27-CV-10-28862

197


et al

i.e.

i.e.

et al et al et al

et al

et al

et al

et al et al

e.g.

i.e.

et al et al

et al et al

27-CV-10-28862

198


11.1.2 Bioaccumulation

et al et al et al

e.g.

et al

11.2 Overview of the Chronology of 3M Scientific Knowledge and Actions

11.2.1 1970s

e.g. et al

et al

et al

et al

e.g.

e.g. et al

27-CV-10-28862

199


et al

et al et al

11.2.2 1980s

et al

et al

et al

i.e

27-CV-10-28862

200


et al

11.2.3 1990s

via

i.e.

27-CV-10-28862

201


et al

et al

et al

et al

et al.

e.g

11.4.4 Early 2000s

could potentially pose a risk to human health and the environment

27-CV-10-28862

202


11.3 Summary

via

via

i.e

via

27-CV-10-28862

203


27-CV-10-28862

204


12 Awareness of Health Risks from Waste Disposal

12.1 Waste Disposal and Contamination of Groundwater

27-CV-10-28862

205


27-CV-10-28862

206


12.2 Awareness of Chemicals in the Environment

Silent Spring

Silent Spring

e.g

Risk Assessment in the Federal Government: Managing the Process

27-CV-10-28862

207


i.e

12.3 Summary

e.g

27-CV-10-28862

208


13 Comments on Plaintiff's Opinions

13.1 Comments on Dr. DeWitt's Opinions

27-CV-10-28862

209


13.1.1 Cancer

i.e

et al.

et al.

e.g. et al. et al. et al

et al

et al

27-CV-10-28862

210


et al

et al

i.e. et al

via

et al

§ et al

§ via

et al

et al

§ et al

et al

c-jun c-myc

27-CV-10-28862

211


et al c-myc

et al

et al

e.g

via

27-CV-10-28862

212


13.1.2 Developmental Toxicity

et al

et al

et al et al

27-CV-10-28862

213


et al

et al

et al

13.1.3 Immunotoxicity

vs

et al

et al

et al

i.e

et al

et al

et al

et al

27-CV-10-28862

214


et al

et al et al

et al.

13.1.4 Thyroid Disease

et al

et al et al et al

27-CV-10-28862

215


i.e

13.1.5 Consideration of Dose

et al

et al

et al

et al

et al

et al

et al

27-CV-10-28862

216


13.1.6 Consideration of Causation

13.1.7 Consideration of Risk Assessment

e.g

per se

13.1.8 Drinking Water Guidance

et al et al

et al

et al

i.e

27-CV-10-28862

217


et al

13.1.9 State of Knowledge

1963 FC-95 LD50

1978 Monkey Study

et al

via

et al

27-CV-10-28862

218


1980-1983 PFC Teratology

i.e

et al

via

et al

27-CV-10-28862

219


e.g et al

et al.

e.g.

13.1.10 Appendix B: Estimating "Safe" PFOS Doses

circa

13.2 Comments on Dr. Grandjean's Opinions

27-CV-10-28862

220


versus

13.2.1 Immunotoxicity

Epidemiological Evidence

et al

i.e

27-CV-10-28862

221


i.e.

et al et al

increased

et al

p Haemophilus

influenzae

et al et al

et al

27-CV-10-28862

222


et al

et al

Toxicological Evidence

et al et al et al

et al.

27-CV-10-28862

223


13.2.2 Reproductive and Developmental Outcomes


e.g

Reproductive Effects. et

al

et al

et al

et al

et al

et al

inverse

27-CV-10-28862

224


i.e

et al et al

et al

Developmental Toxicity and Birth Defects.

et al

et al

et al et al

et al et al et al et al et al et al

27-CV-10-28862

225


e.g et al et al

Endocrine Effects.

adverse i.e

i.e

i.e et al

et

al


et al

e.g et al.

13.2.3 Cancer


27-CV-10-28862

226


e.g

Prostate Cancer.

et al.

27-CV-10-28862

227


et al

et al

et al

e.g et al

Kidney Cancer.

et al

et al

et al

et al

et al

et al et al

et al

27-CV-10-28862

228


Testicular Cancer.

et

al et al

et al

et al

i.e


et al

et al

et al et al

27-CV-10-28862

229


13.2.4 Other Endpoints

et al

et al

et al

13.2.5 State of Knowledge

General Comments

§

27-CV-10-28862

230


revealed a strategy to pursue studies that might benefit company interests

§

§

e.g

e.g.

e.g

i.e

et al

i.e.

et al et al

27-CV-10-28862

231


Specific Examples

et al

et al

e.g et al

27-CV-10-28862

232


i.e

et al

et al et al

et al

et al

i.e.

27-CV-10-28862

233


et al

i.e

et al

et al

et al

i.e

et al

27-CV-10-28862

234


13.2.6 Serum Analyses from Minnesota Residents

13.2.7 Alternative Drinking Water Limits

circa

et al

i.e

27-CV-10-28862

235


et al

i.e

i.e

13.3 Comments on Dr. Sunding's Opinions

et al

e.g

Adverse Birth Outcomes

27-CV-10-28862

236


Fertility

Cancer Incidence

i.e

27-CV-10-28862

237


References

Toxicol. Sci.

27-CV-10-28862

238


Reprod. Toxicol.

Toxicol. Sci.

Ann. Epidemiol.

27-CV-10-28862

239


Occup. Environ. Med.

Am. J. Epidemiol.

Am. J. Epidemiol.

Toxicology

J. Biol. Chem.

Environ. Health Perspect.

Environ. Rev.

Toxicology

27-CV-10-28862

240



Environ. Health

Crit. Rev. Toxicol.

Regul. Toxicol. Pharmacol.



versus Science

Anal. Biochem.

Environ. Int.

Annu. Rev. Med.

Toxicol. Sci.

27-CV-10-28862

241


Toxicol. Sci.

Toxicol. Sci.

Environ. Int.

Toxicol. Sci.

Toxicology

Chemosphere

Environ. Health


Reprod. Toxicol.

Environ. Int.

Obesity

27-CV-10-28862

242


Toxicological

Effects of Perfluoroalkyl and Polyfluoroalkyl Substances

Environ.

Health Perspect.

Goodman and Gilman's The

Pharmacological Basis of Therapeutics (Eleventh Edition)

Methods in

Immunotoxicology: Volume I

Environment

Toxicol. Sci.

Reprod. Toxicol.

Reprod. Toxicol.

Toxicology

Reprod. Toxicol.

Regul. Toxicol.

Pharmacol.

Toxicology

Toxicology

27-CV-10-28862

243


Toxicol.

Sci.



27-CV-10-28862

244


Werner & Ingbar's The Thyroid: A

Fundamental and Clinical Text (Eighth Edition)

Werner & Ingbar's The

Thyroid: A Fundamental and Clinical Text (Eighth Edition)

Int. J. Toxicol.

Toxicol. Rep.

27-CV-10-28862

245


via Toxicol. Sci.

Reprod. Toxicol.

Toxicol. Sci.

Reprod. Toxicol.

Toxicology

Toxicology

PLoS ONE

Reprod. Toxicol.

Cancer Res.

Werner &

Ingbar's The Thyroid: A Fundamental and Clinical Text (Eighth Edition)

Environ. Int.

27-CV-10-28862

246


Food Addit. Contam. Part A

Chem. Anal. Control Expo. Risk Assess.


Curr. Opin.

Toxicol.

Toxicol. Sci.

In Vivo

The Road to Love Canal: Managing Industrial Waste Before EPA

Environ.

Sci. Technol.

In vitro Toxicol. Appl.

Pharmacol.

Crit. Rev. Toxicol.

J. Occup. Environ. Med.

27-CV-10-28862

247


Arch. Environ. Contam. Toxicol.

J. Toxicol. Environ. Health A

Toxicological Effects of

Perfluoroalkyl and Polyfluoroalkyl Substances

Environ. Int.

Environ.

Health Perspect.

Epidemiology

Environ.

Health Perspect.

Toxicol. Sci.

Toxicology

J. Expo. Sci.

Environ. Epidemiol.

Nat. Rev. Immunol.

27-CV-10-28862

248


Toxicological Effects of Perfluoroalkyl and Polyfluoroalkyl Substances

Toxicol. Sci.


a

J. Immunotoxicol.

Environ. Res.

Methods in Immunotoxicology: Volume I. (Eds.: Burleson,

GR; Dean, JH; Munson, AE)

Diabetes Care

Food Chem.

Arch. Toxicol.

Arch. Toxicol.

Environ. Int.

27-CV-10-28862

249


Occupational Toxicology

(Second Edition)

Casarett and Doull's Toxicology: The Basic

Science of Poisons (Eighth Edition)

J. Expo. Sci.

Environ. Epidemiol.

Environ. Res.

Toxicology

Toxicology

Arch. Toxicol.


PLoS ONE

J. Natl. Cancer Inst.

27-CV-10-28862

250


Toxicology

EFSA J.

EFSA J.

in vitro Drug Chem. Toxicol.

Mayo Clin.

Proc.

Casarett and Doull's Toxicology: The Basic

Science of Poisons (Eighth Edition)


Hum. Reprod.

Environ. Res.


Am. J. Epidemiol.

Toxicol. Sci.

Toxicol. Pathol.

27-CV-10-28862

251


J. Environ.

Sci. Health C Environ. Carcinog. Ecotoxicol. Rev.

Epidemiology

Goodman and Gilman's The Pharmacological

Basis of Therapeutics (Eleventh Edition)

Toxicol. Sci.

Hayes' Principles and Methods of Toxicology (Sixth Edition)


Arch. Pediatr. Adolesc. Med.

Int. J. Hyg. Environ. Health

Ecotoxicol. Environ. Saf.

Toxicol. Sci.

J. Occup.

Health

27-CV-10-28862

252


Environ.

Health Perspect.

Environ. Int.


Chemosphere

Environ. Sci.

Technol.

J. Occup. Med.

Am. J. Ind. Med.

Environ. Res.

27-CV-10-28862

253


Circulation

Toxicology

Atlas of Toxicological Pathology

Environ. Int.

et al. v

27-CV-10-28862

254


JAMA

Environ. Health

Perspect.

J. Immunotoxicol.

Birth Defects Res. B

Dev. Reprod. Toxicol.

Birth Defects Res. A Clin. Mol. Teratol.

CA Cancer J.

Clin.


Am. Ind.

Hyg. Assoc. J.

Environ. Sci. Technol.

Biochemistry Involving Carbon-Fluorine Bonds

Textbook of Medical Physiology (Tenth Edition)

Toxicol. Pathol.

J. Expo. Sci. Environ. Epidemiol.

Chem. Res. Toxicol.

27-CV-10-28862

255


Proc. Soc. Exp. Biol. Med.


Environ. Res.

Environ. Toxicol. Pharmacol.

Environ. Int.

Drug Chem. Toxicol.

Chemosphere

Environ. Int.

Hayes' Principles and Methods of Toxicology (Sixth Edition)

Epidemiology in Medicine

Epidemiology in Medicine

Hum. Ecol. Risk Assess.

Proc. R. Soc. Med.

27-CV-10-28862

256


Toxicology

Toxicology



Methods in Immunotoxicology: Volume I

Toxicol. Sci.


Environ. Health

J. Immunotoxicol.

Drug Chem. Toxicol.

J. Biochem.

BMC Cancer

27-CV-10-28862

257


IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume

110: Some Chemicals Used as Solvents in Polymer Manufacture

Gen. Pharmacol.

Arch. Toxicol.

J. Toxicol. Sci.

Drug

Chem. Toxicol.

Environ. Res.

Hum. Exp. Toxicol.

Immunobiology: The Immune System in Health and Disease (Fifth Edition)

Immunobiology: The Immune System in Health and Disease (Fifth Edition)

27-CV-10-28862

259


PLoS ONE

Hum. Reprod.

Neurotoxicology

Nephrol. Dial. Transplant.

Environ. Health

Environ.

Res.

Casarett and Doull's Toxicology: The Basic Science of Poisons (Eighth Edition)

Environ. Res.



27-CV-10-28862

259




J. Pharmacol. Exp. Ther.

Toxicology

Toxicol. Pathol.

Toxicol. Sci.

Toxicol. Sci.

Int. J. Dev. Biol.

Toxicol. Appl. Pharmacol.

Food Chem. Toxicol.

Crit. Rev. Toxicol.

Toxicological

Effects of Perfluoroalkyl and Polyfluoroalkyl Substances

Drug Chem. Toxicol.

27-CV-10-28862

260


Toxicol. Pathol.



J. Immunotoxicol.

Food

Chem. Toxicol.


Casarett and Doull's Toxicology: The Basic Science of

Poisons (Eighth Edition)

Crit. Rev. Toxicol.

Food Addit. Contam. Part A Chem.

Anal. Control Expo. Risk Assess.

J. Toxicol. Sci.

J. Clin. Endocrinol. Metab.

Principles and Methods of Toxicology (Fourth Edition)

27-CV-10-28862

261


Hum. Reprod.

J. Biol. Chem.

Chem. Biol.

Interact.

Chem. Biol. Interact.

Biol. Pharm. Bull.

Chem. Biol.

Interact.

in vitro PLoS ONE


J. Environ. Health

Toxicological Effects of Perfluoroalkyl and

Polyfluoroalkyl Substances


Toxicol. Sci.

27-CV-10-28862

262


Toxicol. Sci.

ENS Int. Newswire

Environ. Hist. Rev.

Endocrinology

Neurotoxicology

Mol.

Cell. Biol.

J. Toxicol.

Environ. Health A

Casarett and

Doull's Toxicology: The Basic Science of Poisons (Eighth Edition)

Ann.

Epidemiol.

Hamilton and Hardy's Industrial

Toxicology (Sixth Edition)


Toxicologist

Toxicol. Pathol.

27-CV-10-28862

263


Environ. Int.

Sci. Rep.

Toxicology

Toxicology

Chemosphere


Am. J.

Gastroenterol.

Int. J. Cardiol.

J. Hazard. Mater.



Fundam.

Appl. Toxicol.

27-CV-10-28862

264


Am. J. Physiol. Renal Physiol.

Reprod. Toxicol.

Reprod. Toxicol.

J. Toxicol.

Environ. Health A

Toxicol. Sci.




Reprod. Toxicol.

Toxicology

Toxicol. Sci.

BMC Pharmacol.

27-CV-10-28862

265


Toxicology

in

utero

Toxicology

Comput. Methods Programs Biomed.

Clin. Chem.

Epidemiology

Fundam. Appl. Toxicol.

Hum.

Reprod.

Toxicol. Sci.




27-CV-10-28862

266


Guides for Toxicologic Pathology

Toxicol. Sci.

Environ. Res.


Ind. Health

27-CV-10-28862

267


vs

et al. vs

27-CV-10-28862

268


27-CV-10-28862

269


27-CV-10-28862

270



Federal Environmental Law: The User's Guide

Basic Clin. Pharmacol. Toxicol.

Toxicology

Risk Assessment in the Federal Government: Managing the

Process

Ground Water Quality Protection: State and Local Strategies

Intentional Human Dosing Studies for EPA Regulatory Purposes: Scientific and Ethical Issues

Health Implications of Perchlorate Ingestion

27-CV-10-28862

271


Science and Decisions: Advancing Risk Assessment.[The Silver

Book].

Environ. Health

In utero

Environ. Res.

Reprod. Toxicol.

J. Agric.

Food Chem.

PLoS ONE

Toxicology

Environ. Int.

27-CV-10-28862

272


Environ. Res.



Drug Chem. Toxicol.




Hayes' Principles and

Methods of Toxicology (Sixth Edition)

Toxicology


J.


27-CV-10-28862

273



AIHA J. (Fairfax, Va)

Environ. Res.

Int. Arch. Occup.

Environ. Health

Toxicol. Sci.

Toxicol. Pathol.

Mol. Pharmacol.

27-CV-10-28862

274


Hayes' Principles and Methods

of Toxicology (Sixth Edition)

Toxicol. Sci.

Toxicol. Sci.

Environ. Int.

Drug Chem. Toxicol.

Biochem. Pharmacol.

Xenobiotica


Toxicology

Int. J. Environ. Res. Public Health

27-CV-10-28862

275



Int. J. Environ. Res. Public

Health

Reprod. Toxicol.

Toxicol. Rep.



Am. J. Epidemiol.


27-CV-10-28862

276


Goodman and Gilman's The Pharmacological Basis

of Therapeutics (Tenth Edition)


Environ. Res.

Toxicol. Pathol.

Toxicol. Sci.

Toxicology

Ambix

The Polluters: The Making of Our Chemically Altered Environment




Epidemiology


27-CV-10-28862

277


Environ. Sci.

Technol.


Int. J. Hyg. Environ.

Health

Toxicology

Toxicol. Sci.


Am. J. Epidemiol.

Massachusetts Environmental

Law, Volume II (1996 Edition)

Casarett and Doull's Toxicology: The Basic Science of Poisons

(Eighth Edition)

Environ. Int.

Allergy

27-CV-10-28862

278


Casarett and Doull's Toxicology: The Basic Science of

Poisons (Fifth Edition)

In vitro Methods in

Immunotoxicology: Volume I

Biochem. J.

Pharmacol. Toxicol.

Arch. Toxicol.

Ecotoxicol. Environ. Saf.

Fundam. Appl. Toxicol.

Am. J.

Epidemiol.

Environ. Int.


Epidemiology

Am. J.

Epidemiol.

27-CV-10-28862

279



Am. J. Epidemiol.



Am. J. Epidemiol.

Environ. Int.

Developmental and Reproductive Toxicology: A Practical Approach (Third Edition)

v

Toxicol.

Sci.

Werner & Ingbar's The

Thyroid: A Fundamental and Clinical Text (Eighth Edition)

Nature

27-CV-10-28862

280



Toxicol. Sci.

J. Toxicol. Environ. Health B Crit. Rev.

Environ. Int.

J. Immunotoxicol.

J. Clin. Endocrinol. Metab.

via

J. Agric. Food Chem.

Manual for the Surveillance of Vaccine-Preventable Diseases (Fifth

Edition)

27-CV-10-28862

281



Arch.

Environ. Health

Int. J. Hyg. Environ. Health


Reprod. Toxicol.

Am. Ind. Hyg. Assoc. J.

27-CV-10-28862

282


Fed.

Reg.

27-CV-10-28862

283


Fed. Reg.

27-CV-10-28862

expert report of barbara d. beck, ph.d., dabt, ats, ert in the...

Documents